<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3107222370
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        IMNOVID 2 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        POMALIDOMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27953.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CELGENE INTERNATIONAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CELGENE INTERNATIONAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Bristol-Myers Squibb / Pharma EEIG 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AX06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Imnovid is</p><p>Imnovid contains the active substance &lsquo;pomalidomide&rsquo;. This medicine is related to thalidomide and belongs to a group of medicines which affect the immune system (the body&rsquo;s natural defences).</p><p>What Imnovid is used for</p><p>Imnovid is used to treat adults with a type of cancer called &lsquo;multiple myeloma&rsquo;.</p><p>Imnovid is either used with:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>two other medicines </strong>- called &lsquo;bortezomib&rsquo; (a type of chemotherapy medicine) and &lsquo;dexamethasone&rsquo; (an anti-inflammatory medicine) in people who have had at least one other treatment - including lenalidomide.</p><p>Or</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>one other medicine </strong>- called &lsquo;dexamethasone&rsquo; in people whose myeloma has become worse, despite having at least two other treatments - including lenalidomide and bortezomib.</p><p>What is multiple myeloma</p><p>Multiple myeloma is a type of cancer which affects a certain type of white blood cell (called the &lsquo;plasma cell&rsquo;). These cells grow out of control and accumulate in the bone marrow. This results in damage to the bones and kidneys.</p><p>Multiple myeloma generally cannot be cured. However, treatment can reduce the signs and symptoms of the disease, or make them disappear for a period of time. When this happens, it is called &lsquo;response&rsquo;.</p><p>How Imnovid works</p><p>Imnovid works in a number of different ways:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by stopping the myeloma cells developing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by stimulating the immune system to attack the cancer cells</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by stopping the formation of blood vessels supplying the cancer cells.</p><p>The benefit of using Imnovid with bortezomib and dexamethasone</p><p>When Imnovid is used with bortezomib and dexamethasone, in people who have had at least one other treatment, it can stop multiple myeloma getting worse:</p><p>&nbsp;&nbsp; On average, Imnovid when used with bortezomib and dexamethasone stopped multiple myeloma from coming back for up to 11 months - compared with 7 months for those patients who only used bortezomib and dexamethasone.</p><p>The benefit of using Imnovid with dexamethasone</p><p>When Imnovid is used with dexamethasone, in people who have had at least two other treatments, it can stop multiple myeloma getting worse:</p><p>&nbsp;&nbsp;&nbsp; On average, Imnovid when used with dexamethasone stopped multiple myeloma from coming back for up to 4 months compared with 2 months for those patients who used only dexamethasone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You will have been given specific instructions by your doctor, particularly on the effects of Imnovid on unborn babies (outlined in the <em>i-SECURE </em>program).</p><p>You will have been given an Imnovid <em>i-SECURE </em>Patient Brochure by your doctor. Read it carefully and follow the related instructions.</p><p>If you do not fully understand these instructions, please ask your doctor to explain them again <strong>before you take Imnovid</strong>. See also further information in this section under &ldquo;Pregnancy, contraception and breastfeeding&rdquo;.</p><p><strong>Do not take Imnovid:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or think you may be pregnant or are planning to become pregnant &ndash; this is because <strong>Imnovid is expected to be harmful to an unborn child</strong>. (Men and women taking this medicine must read the section &ldquo;Pregnancy, contraception and breast-feeding &ndash; information for women and men&rdquo; below).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are able to become pregnant, unless you follow all the necessary measures to prevent you from becoming pregnant (see &ldquo;Pregnancy, contraception and breast-feeding &ndash; information for women and men&rdquo;). If you are able to become pregnant, your doctor will record with each prescription that the necessary measures have been taken and will provide you with this confirmation.</p><p>if you are allergic to pomalidomide or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice.</p><p>If you are uncertain whether any of the conditions above apply to you, talk to your doctor, pharmacist or nurse before taking Imnovid.</p><p>Warnings and precautions</p><p>Talk to your doctor, pharmacist or nurse before taking Imnovid if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had blood clots in the past. During the treatment with Imnovid you have an increased risk of getting blood clots in your veins and arteries. Your doctor may recommend you take additional treatments (e.g. warfarin) or lower the dose of Imnovid to reduce the chance that you get blood clots.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had an allergic reaction such as rash, itching, swelling, feeling dizzy or trouble breathing while taking related medicines called &lsquo;thalidomide&rsquo; or &lsquo;lenalidomide&rsquo;.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had a heart attack, have heart failure, have difficulty breathing, or if you smoke, have high blood pressure or high cholesterol levels.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a high total amount of tumour throughout the body, including your bone marrow. This could lead to a condition where the tumours break down and cause unusual levels of chemicals in the blood which can lead to kidney failure. You may also experience an uneven heartbeat. This condition is called tumour lysis syndrome.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or have had neuropathy (nerve damage causing tingling or pain in your hands or feet).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or have ever had hepatitis B infection. Treatment with Imnovid may cause the hepatitis B virus to become active again in patients who carry the virus, resulting in a recurrence of the infection. Your doctor should check whether you have ever had hepatitis B infection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you experience or have experienced in the past a combination of any of the following symptoms:</p><p>rash on face or extended rash, red skin, high fever, flu-like symptoms, enlarged lymph nodes (signs of severe skin reaction called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) or drug hypersensitivity syndrome, Toxic Epidermal Necrolysis (TEN) or Stevens-Johnson Syndrome (SJS). See also section 4 &ldquo;Possible side effects&rdquo;).</p><p>It is important to note that patients with multiple myeloma treated with pomalidomide may develop additional types of cancer, therefore your doctor should carefully evaluate the benefit and risk when you are prescribed this medicine.</p><p>At any time during or after your treatment, tell your doctor or nurse immediately if you:</p><p>experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion. These may all be symptoms of a serious and potentially fatal brain condition known as progressive multifocal leukoencephalopathy (PML). If you had these symptoms prior to treatment with Imnovid, tell your doctor about any change in these symptoms.</p><p>Pregnancy, contraception and breast-feeding &ndash; information for women and men</p><p>The following must be followed as stated in the Pomalidomide <em>i-SECURE </em>Pregnancy Prevention Programme.</p><p>Women and men taking Imnovid must not become pregnant or father a child. This is because pomalidomide is expected to harm the unborn baby. You and your partner should use effective methods of contraception while taking this medicine.</p><p>Women</p><p>Do not take Imnovid if you are pregnant, think you may be pregnant or are planning to become pregnant. This is because this medicine is expected to harm the unborn baby. Before starting the treatment, you should tell your doctor if you are able to become pregnant, even if you think this is unlikely.</p><p>If you are able to become pregnant:</p><p>&nbsp;</p><p>you must use effective methods of contraception for at least 4 weeks before starting treatment, for the whole time you are taking treatment, and until at least 4 weeks after stopping treatment. Talk to your doctor about the best method of contraception for you.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each time your doctor writes a prescription for you, he will ensure you understand the necessary measures that have to be taken to prevent pregnancy.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your doctor will arrange pregnancy tests before treatment, at least every 4 weeks during treatment, and at least 4 weeks after the treatment has finished</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><em>Breast-feeding</em></p><p>It is not known if Imnovid passes into human breast milk. Tell your doctor if you are breast-feeding or intend to breast-feed. Your doctor will advise if you should stop or continue breast-feeding.</p><p>Men</p><p>Imnovid passes into human semen.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your partner is pregnant or able to become pregnant, you must use condoms for the whole time you are taking treatment and for 7 days after the end of treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your partner becomes pregnant while you are taking Imnovid, tell your doctor straight away. Your partner should also tell her doctor straight away.</p><p>You should not donate semen or sperm during treatment and for 7 days after the end of treatment.</p><p>Blood donation and blood tests</p><p>You should not donate blood during treatment and for 7 days after the end of treatment.</p><p>Before and during the treatment with Imnovid you will have regular blood tests. This is because your medicine may cause a fall in the number of blood cells that help fight infection (white cells) and in the number of cells that help to stop bleeding (platelets).</p><p>Your doctor should ask you to have a blood test: &nbsp;&nbsp;&nbsp;&nbsp; before treatment</p><p>every week for the first 8 weeks of treatment</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at least every month after that for as long as you are taking Imnovid.</p><p>As a result of these tests, your doctor may change your dose of Imnovid or stop your treatment. The doctor may also change the dose or stop the medicine because of your general health.</p><p><strong>Children and adolescents </strong></p><p>Imnovid is not recommended for use in children and young people under 18 years.</p><p>Other medicines and Imnovid</p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This is because Imnovid can affect the way some other medicines work. Also some other medicines can affect the way Imnovid works.</p><p>In particular, tell your doctor, pharmacist or nurse before taking Imnovid if you are taking any of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antifungals such as ketaconazole</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antibiotics (for example ciprofloxacin, enoxacin) &nbsp;&nbsp; certain antidepressants such as fluvoxamine.</p><p>Driving and using machines</p><p>Some people feel tired, dizzy, faint, confused or less alert when taking Imnovid. If this happens to you, do not drive or operate tools or machinery.</p><p>Imnovid contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per capsule, therefore it is considered essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Imnovid must be given to you by a doctor with experience in treating multiple myeloma.</p><p>Always take your medicines exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>When to take Imnovid with other medicines</p><p>Imnovid with bortezomib and dexamethasone</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See the leaflets that come with bortezomib and dexamethasone for further information on their use and effects.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Imnovid, bortezomib and dexamethasone are taken in &lsquo;treatment cycles&rsquo;. Each cycle lasts 21 days (3 weeks).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Look at the chart below to see what to take on each day of the 3-week cycle:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each day, look down the chart and find the correct day to see which medicines to take.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some days, you take all 3 medicines, some days just 2 or 1 medicines, and some days none at all.</p><p><strong>IMN: </strong>Imnovid; <strong>BOR</strong>: Bortezomib; <strong>DEX</strong>: Dexamethasone</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycle 1 to 8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycle 9 and onwards</p><table border="0" cellspacing="0" cellpadding="0" style="width:583px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Medicine name</strong></p></td><td rowspan="23" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Medicine name</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Day</strong></p></td><td style="vertical-align:top"><p><strong>IMN</strong></p></td><td style="vertical-align:top"><p><strong>BOR</strong></p></td><td style="vertical-align:top"><p><strong>DEX</strong></p></td><td style="vertical-align:top"><p><strong>Day</strong></p></td><td style="vertical-align:top"><p><strong>IMN</strong></p></td><td style="vertical-align:top"><p><strong>BOR</strong></p></td><td style="vertical-align:top"><p><strong>DEX</strong></p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After completing each 3-week cycle, start a new one.</p><p>Imnovid with dexamethasone only</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See the leaflet that comes with dexamethasone for further information on its use and effects.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Imnovid and dexamethasone are taken in &lsquo;treatment cycles&rsquo;. Each cycle lasts 28 days (4 weeks).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Look at the chart below to see what to take on each day of the 4-week cycle:</p><p>o Each day, look down the chart and find the correct day to see which medicines to take. o&nbsp; Some days, you take both medicines, some days just 1 medicine, and some days none at all.</p><p><strong>IMN: </strong>Imnovid; <strong>DEX</strong>: Dexamethasone</p><table border="0" cellspacing="0" cellpadding="0" style="width:177px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Medicine name</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Day</strong></p></td><td style="vertical-align:top"><p><strong>IMN</strong></p></td><td style="vertical-align:top"><p><strong>DEX</strong></p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:177px"><tbody><tr><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After completing each 4-week cycle, start a new one.</p><p>How much Imnovid to take with other medicines</p><p>Imnovid with bortezomib and dexamethasone</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended starting dose of Imnovid is 4 mg per day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended starting dose of bortezomib will be worked out by your doctor and based on your height and weight (1.3 mg/m<sup>2 </sup>body surface area).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended starting dose of dexamethasone is 20 mg per day. However, if you are over 75, the recommended starting dose is 10 mg per day.</p><p>Imnovid with dexamethasone only</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose of Imnovid is 4 mg per day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended starting dose of dexamethasone is 40 mg per day. However, if you are over 75, the recommended starting dose is 20 mg per day.</p><p>Your doctor may need to reduce the dose of Imnovid, bortezomib or dexamethasone or stop one or more of these medicines based on the results of your blood tests, your general condition, other medicines you may be taking (e.g. ciprofloxacin, enoxacin and fluvoxamine) and if you experience side effects (especially rash or swelling) from treatment.</p><p>If you suffer from liver or kidney problems your doctor will check your condition very carefully whilst you are receiving this medicine.</p><p>How to take Imnovid</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not break, open or chew the capsules. If powder from a broken Imnovid capsule makes contact with the skin, wash the skin immediately and thoroughly with soap and water.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the capsules whole, preferably with water.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take the capsules either with or without food.</p><p>Take Imnovid at about the same time each day.</p><p>To remove the capsule from the blister, press only one end of the capsule out to push it through the foil. Do not apply pressure on the centre of the capsule as this can cause it to break.</p><p><img alt="" width="609" height="802" src="data:image/png;base64,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" /></p><p>Your doctor will advise you of how and when to take Imnovid if you have kidney problems and are receiving dialysis treatment.</p><p><strong>Duration of the treatment with Imnovid</strong></p><p>You should continue the cycles of treatment until your doctor tells you to stop.</p><p>If you take more Imnovid than you should</p><p>If you take more Imnovid than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you.</p><p>If you forget to take Imnovid</p><p>If you forget to take Imnovid on a day when you should, take your next capsule as normal the next day. Do not increase the number of capsules you take to make up for not taking Imnovid the previous day.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects</p><p><strong>Stop taking Imnovid and see a doctor straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, chills, sore throat, cough, mouth ulcers or any other signs of infection (due to less white blood cells, which fight infection).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding or bruising without a cause, including nosebleeds and bleeding from the bowels or stomach (due to effects on blood cells called &lsquo;platelets&rsquo;).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid breathing, rapid pulse, fever and chills, passing very little to no urine, nausea and vomiting, confusion, unconsciousness (due to infection of blood called sepsis or septic shock).</p><p>Severe, persistent or bloody diarrhoea (possibly with stomach pain or fever) caused by bacteria called <em>Clostridium difficile</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain, or leg pain and swelling, especially in your lower leg or calves (caused by blood clots).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath (from serious chest infection, inflammation of the lung, heart failure or blood clot).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of face, lips, tongue and throat, which may cause difficulty breathing (due to a serious type of allergic reaction called angioedema).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain types of skin cancer (squamous cell carcinoma and basal cell carcinoma), which can cause changes in the appearance of your skin or growths on your skin. If you notice any changes to your skin whilst taking Imnovid, tell your doctor as soon as possible.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrence of hepatitis B infection, which can cause yellowing of the skin and eyes, dark browncoloured urine, right-sided abdominal pain, fever and feeling nauseous or being sick. Tell your doctor straightaway if you notice any of these symptoms.</p><p><strong>Stop taking Imnovid and see a doctor straight away </strong>if you notice any of the serious side effects listed above &ndash; you may need urgent medical treatment.</p><p>Other side effects</p><p><strong>Very common </strong>(may affect more than 1 in 10 people):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath (dyspnoea).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the lungs (pneumonia and bronchitis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the nose, sinuses and throat, caused by bacteria or viruses.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low red blood cells, which may cause anaemia leading to tiredness and weakness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood levels of potassium (hypokalaemia), which may cause weakness, muscle cramps, muscle aches, palpitations, tingling or numbness, dyspnoea, mood changes. &nbsp;&nbsp; High blood levels of sugar.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation, diarrhoea or nausea. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick (vomiting).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of energy.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in falling asleep or staying asleep.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, tremor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle spasm, muscle weakness. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone pain, back pain.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness, tingling or burning sensation to the skin, pains in hands or feet (peripheral sensory neuropathy).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the body, including swelling of the arms or legs.</p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fall.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding within the skull.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased ability to move or feel (sensation) in your hands, arms, feet and legs because of nerve damage (peripheral sensorimotor neuropathy).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness, itching, and a feeling of pins and needles on your skin (paraesthesia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A spinning feeling in your head, making it difficult to stand up and move normally.</p><p>Swelling caused by fluid.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (urticaria).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rashes.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy skin. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingles.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A fast and irregular heartbeat (atrial fibrillation).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack (chest pain spreading to the arms, neck, jaw, feeling sweaty and breathless, feeling sick or vomiting).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain, chest infection. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood pressure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A fall in the number of red and white blood cells and platelets at the same time (pancytopenia), which will make you more prone to bleeding and bruising. You may feel tired and weak, and short of breath and you are also more likely to get infections.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased number of lymphocytes (one type of white blood cells) often caused by infection (lymphopenia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood levels of magnesium (hypomagnesaemia), which may cause tiredness, generalised weakness, muscle cramps, irritability and may result in low blood levels of calcium (hypocalcaemia), which may cause numbness and, or tingling of hands, feet, or lips, muscle cramps, muscle weakness, light-headedness, confusion.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood level of phosphate (hypophosphataemia), which may cause muscle weakness and irritability or confusion.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood level of calcium (hypercalcaemia), which may cause slowing reflexes and skeletal muscle weaknesses.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood levels of potassium, which may cause abnormal heart rhythm.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood levels of sodium, which may cause tiredness and confusion, muscle twitching, fits (epileptic seizures) or coma.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood levels of uric acid, which may cause a form of arthritis called gout. &nbsp;&nbsp; Low blood pressure, which may cause dizziness or fainting.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like symptoms (influenza).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore or dry mouth.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the way things taste.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain, swollen abdomen.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling confused.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling down (depressed mood).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of consciousness, fainting.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clouding of your eye (cataract).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damage to the kidney.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability to pass urine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver test.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection, which may cause a burning sensation when passing urine, or a need to pass urine more often.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the pelvis. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stroke.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the liver (hepatitis) which can cause itchy skin, yellowing of the skin and the whites of the eyes (jaundice), pale coloured stools, dark coloured urine and abdominal pain.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The breakdown of cancer cells resulting in the release of toxic compounds into the bloodstream (tumour lysis syndrome). This can result in kidney problems.</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Widespread rash, high body temperature, enlarged lymph nodes and other body organs involvement (Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome, Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome). Stop using pomalidomide if you develop these symptoms and contact your doctor or seek medical attention immediately. See also section 2.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30<sup>o</sup>C.</p><p>Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date refers to the last day of that month.</p><p>Do not use Imnovid if you notice any damage or signs of tampering to medicine packaging.</p><p>Do not throw away any medicines via wastewater or household waste. Any unused medicine should be returned to the pharmacist at the end of treatment. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is pomalidomide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are mannitol (E421), starch, pregelatinised, and sodium stearyl fumarate.</p><p>Imnovid 1 mg hard capsule:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each capsule contains 1 mg of pomalidomide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132) and yellow iron oxide (E172) and white and black ink.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: shellac, titanium dioxide (E171), simeticone, propylene glycol (E1520) and ammonium hydroxide (E527) (white ink) and shellac, iron oxide black (E172), propylene glycol (E1520) and ammonium hydroxide (E527) (black ink).</p><p>Imnovid 2 mg hard capsule:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each capsule contains 2 mg of pomalidomide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132), yellow iron oxide (E172), erythrosin (E127) and white ink.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: white ink - shellac, titanium dioxide (E171), simeticone, propylene glycol (E1520) and ammonium hydroxide (E527).</p><p>Imnovid 3 mg hard capsule:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each capsule contains 3 mg of pomalidomide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132), yellow iron oxide (E172) and white ink.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: white ink - shellac, titanium dioxide (E171), simeticone, propylene glycol (E1520) and ammonium hydroxide (E527).</p><p>Imnovid 4 mg hard capsule:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each capsule contains 4 mg of pomalidomide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132), brilliant blue FCF (E133), and white ink.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: white ink - shellac, titanium dioxide (E171), simeticone, propylene glycol (E1520) and ammonium hydroxide (E527).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Imnovid 1 mg hard capsules: Dark blue opaque cap and yellow opaque body, with “POML 1 mg” written on them.
Imnovid 2 mg hard capsules: Dark blue opaque cap and orange opaque body, with “POML 2 mg” written on them.
Imnovid 3 mg hard capsules: Dark blue opaque cap and green opaque body, with “POML 3 mg” written on them.
Imnovid 4 mg hard capsules: Dark blue opaque cap and blue opaque body, with “POML 4 mg” written on them.
Each pack contains 21 capsules: (3 blisters x 7 capsules)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p>Bristol-Myers Squibb Pharma EEIG&nbsp;</p><p>Plaza 254</p><p>Blanchardstown Corporate Park 2</p><p>Dublin 15, D15 T867</p><p>Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in August 2021 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما ھو إمنوفید</strong>&nbsp;</p><p dir="RTL">یحتوي إمنوفید على المادة الفعالة&#39; بومالیدوماید&#39;. ھذا الدواء ھو ذو صلة بالثالیدوماید وینتمي إلى مجموعة من الأدویة التي تؤثر على الجھاز المناعي (الدفاعات الطبیعیة في الجسم).&nbsp;&nbsp;</p><p dir="RTL"><strong>ما ھي دواعي استعمال إمنوفید</strong></p><p>&nbsp;</p><p dir="RTL">یستعمل إمنوفید لعلاج البالغین الذین یعانون من نوع من السرطان یسمى&#39;الورم النقوي المتعدد&#39;.</p><p dir="RTL">إمنوفید یستخدم إما مع:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواءان آخران - ُیُدُعى &quot;بورتیزومیب&quot; (نوع من دواء العلاج الكیمیائي) و &quot;دیكسامیثازون&quot; (دواء مضاد للالتھابات) في الأشخاص الذین تلقوا علاًجًا واحدًا آخر على الأقل - بما في ذلك اللینالیدومید.</p><p dir="RTL">أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء آخر&nbsp; - یسمى &quot;دیكسامیثازون&quot; من قبل الأشخاص الذین أصبح عندھم الورم النقوي أسوأ، على الرغم من تناولھم على الأقل نوعین من أنواع العلاجات الأخرى، بما في ذلك لینالیدوماید و بورتیزومیب.</p><p dir="RTL"><strong>ما ھو الورم النقوي المتعدد</strong>&nbsp;</p><p dir="RTL">الورم النقوي المتعدد ھو نوع من أنواع السرطان الذي یؤثر على نوع معین من خلایا الدم البیضاء (تسمى &#39;خلیة البلازما&#39;).</p><p dir="RTL">ھذه الخلایا تنمو خارج نطاق السیطرة و تتراكم في نخاع العظام. وینتج عن ھذا أضرار في العظام و الكلیتین.&nbsp;</p><p dir="RTL">وعمومااً، فإنھ لا یمكن علاج الورم النقوي المتعدد. ومع ذلك، یمكن العلاج أن یقلل من علامات وأعراض المرض، أو جعلھا تختفي لفترة من الزمن. وعندما یحدث ھذا، فإنھ یسمى &#39;الإستجابة&#39;.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>كیف یعمل إمنوفید</strong>&nbsp;</p><p dir="RTL">إمنوفید یعمل في عدد من الطرق المختلفة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من خلال وقف نمو خلایا الورم النقوي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من خلال تحفیز الجھاز المناعي لمھاجمة الخلایا السرطانیة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من خلال وقف تشكیل الأوعیة الدمویة التي تغذي الخلایا السرطانیة.</p><table border="0" cellspacing="0" cellpadding="0" style="width:610px"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">فائدة استخدام إمنوفید مع بورتیزومیب ودیكسامیثازون&nbsp;</p><p dir="RTL">عند استخدام إمنوفید مع بورتیزومیب و دیكسامیثازون، عند الأشخاص الذین خضعوا لعلاج واحد على الأقل یمكن أن یوقف الورم النقوي المتعدد من أن یزداد سوءاً:&nbsp;</p><p dir="RTL">&bull;&nbsp; <!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group
   id="Group_x0020_73423" o:spid="_x0000_s1028" style='width:3.35pt;height:14.15pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_197695" o:spid="_x0000_s1029" style='position:absolute;
    width:42672;height:179832;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l42672,r,179832l,179832,,e" fillcolor="#fdfdfd" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="83231f" joinstyle="miter"/>
    <v:path arrowok="t" textboxrect="0,0,42672,179832"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="4" height="19" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:3.35pt;
   height:14.15pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]-->بالمعدل، عند إستعمال إمنوفید مع بورتیزومیب ودیكسامیثازون فإنھ أوقف عودة الورم النقوي المتعدد لمدة تصل إلى 11شھًرًا&nbsp; مقارنةمقارنةً بـ 7 أشھر لأولئك المرضى الذین إستعملوا بورتیزومیب ودیكسامیثازون فقط.</p></td></tr></tbody></table><p dir="RTL">فائدة استخدام إمنوفید مع دیكسامیثازون&nbsp;</p><p dir="RTL">عندما یستخدم إمنوفید مع دیكسامیثازون، <!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_73779" o:spid="_x0000_s1026"
 style='width:3.35pt;height:14.15pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_197819" o:spid="_x0000_s1027" style='position:absolute;
  width:42672;height:179832;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l42672,r,179832l,179832,,e" fillcolor="#fdfdfd" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,42672,179832"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="5" height="19" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if mso & !supportInlineShapes & supportFields]><span
dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:3.35pt;
 height:14.15pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]-->لدى الأشخاص الذین تلقوا علاجین آخرین على الأقل ، فإنھ یمكن أن یوقف الورم النقوي المتعدد من أن یزداد سوءاً:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المتوسط، عند إستعمال إمنوفید مع دیكسامیثازون فإنھ أوقف عودة الورم النقوي المتعدد لمدة تصل إلى 4أشھر مقارنة مع شھرین لأولئك المرضى الذین إستعملوا دیكسامیثازون فقط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سیكون قد أعطیت لك تعلیمات محددة من قبل الطبیب، وخاصة عن تأثیرات إمنوفید على الأطفال الذین لم یولدوا بعد (الواردة في برنامج <em>i-SECURE</em>).</p><p dir="RTL">وسیكون قد تم إعطاؤك كتیب إمنوفید <em>i-SECURE</em> الخاص بالمریض من قبل الطبیب. إقرأه بعنایة وإتبع الإرشادات ذات الصلة.&nbsp;</p><p dir="RTL">إذا كانت التعلیمات غیر مفھومة لك بشكل تام، الرجاء أن تطلب من طبیبك أن&nbsp; یشرحھا لك مرة أخرى قبل أن تتناول إمنوفید. شاھد أیضا مزیداً من المعلومات في ھذا القسم تحت عنوان &quot;الحمل ومنع الحمل والرضاعة الطبیعیة.&quot;&nbsp;</p><p dir="RTL"><strong>لا تتناولي إمنوفید</strong>:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حامًلاً أو تعتقدي بأنك قد تكوني حامًلاً أوتخططي لتصبحي حامًلاً -<strong> ذلك لأنھ من المتوقع أن یكون إمنوفید ضارااً للطفل الذي لم یولد بعد</strong>. (یجب على الرجال والنساء الذین یتناولون ھذا الدواء قراءة قسم &quot;الحمل ومنع الحمل والرضاعة الطبیعیة - معلومات للنساء والرجال&quot; أدناه.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قادرة على أن تصبحي حاملاحاملاً، إلا إذا كنت تتبعي جمیع التدابیر اللازمة لمنعك من الحمل(&nbsp; الإطلاع على</p><p dir="RTL">&quot;الحمل ومنع الحمل والرضاعة الطبیعیة&nbsp; - معلومات للنساء والرجال&quot;). إذا كنت قادرة على أن تصبحي حامًلاً، فإن طبیبك سوف یسجل مع كل وصفة طبیة أن التدابیر اللازمة قد تم إتخاذھا<!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span> SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_73780" o:spid="_x0000_s1026"
 style='width:3.35pt;height:14.15pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_198705" o:spid="_x0000_s1027" style='position:absolute;
  width:42672;height:179832;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l42672,r,179832l,179832,,e" fillcolor="#fdfdfd" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,42672,179832"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="4" height="18" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:3.35pt;
 height:14.15pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]-->وسیزویدك بھذا التأكید .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسیة لبومالیدوماید أو أي من المكونات الأخرى لھذا الدواء (المدرجة في القسم 6). إذا كنت تعتقدین أنھ قد تكون لدیك حساسیة، فأطلبي المشورة من طبیبك.</p><p>&nbsp;</p><p dir="RTL">إذا كنت غیر متأكدة ما إذا كان أي من الشروط المذكورة أعلاه تنطبق علیك، فتحدثي مع طبیبك أو الصیدلي أو الممرضةقبل تناول إمنوفید.</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>التحذیرات والاحتیاطات</strong>&nbsp;</p><p dir="RTL">تحدث إلى طبیبك أو الصیدلي أو الممرضة قبل تناول إمنوفید إذا:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لدیك في أي وقت مضى جلطات دمویة. خلال العلاج بإمنوفید یكون لدیك زیادة في خطر الإصابة بجلطات دمویة في الأوردة والشرایین. قد یوصي طبیبك أن تتناول علاجات إضافیة (مثل الوارفارین) أو تخفیض جرعة إمنوفید لتقلیل فرصة حصول الجلطات الدمویة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لدیك في أي وقت مضى حساسیة مثل الطفح الجلدي، والحكة والتورم، والشعور بالدوار أو صعوبة في التنفس حین تتناول أدویة ذات صلة تسمى &#39;الثالیدوماید&#39; أو &#39;لینالیدوماید&#39;.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لدیك نوبة قلبیة، قصور في القلب، صعوبة في التنفس، أو إذا كنت تدخن، أو إرتفاع في ضغط الدم أو إرتفاع في مستویات الكولسترول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدیك كمیة عالیة من الورم في جمیع أنحاء الجسم، بما في ذلك نخاع العظم. وھذا یمكن أن یؤدي إلى حالة حیث تتكسر الأورام مؤدیة إلى مستویات غیر عادیة من المواد الكیمیائیة في الدم التي یمكن أن تؤدي إلى الفشل الكلوي. قد تصاب أیضااً بضربات غیر متساویة للقلب. وتسمى ھذه الحالة متلازمة تحلل الورم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدیك أو كان لدیك في أي وقت مضى إعتلال عصبي ( تلف الأعصاب مما یسبب نخز أو ألم في الیدین أو القدمین.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدیك أو كان لدیك في أي وقت مضى التھاب الكبد الفیروسي بي. العلاج باستخدام إمنوفید قد ینشط التھاب الكبد الفیروسي بي لدى المرضى الذین یحملون الفیروس، مما یؤدي إلى عودة الالتھاب. یجب أن یتأكد طبیبك ما إذا كان قدسبق إصابتك بالتھاب الكبد الفیروسي بي.</p><p dir="RTL">&bull; إذا كنت تختبر أو قد اختبرت في الماضي مزیج ًامن أي من الأعراض التالیة: طفح على الوجھ أو طفح جلدي&nbsp;&nbsp;&nbsp; ممتدّ، أوإحمرار الجلد، أو حمى مرتفعة، أو أعراض تشبھ أعراض الانفلونزا، أو&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخّم في العقد اللیمفاویة (علامات تدل على ردفعل جلدي حاد یسمى التفاعلات الدوائیة مع فرط الحمضات الأعراض الجھازیة أو متلازمة فرط الحساسیة للمخدرات أومتلازمة انحلال البشرة النخري السمي (TEN) أو متلازمة ستیفنز جونسون (SJS). أنظر&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أیضًاالجزء 4 &quot;التأثیرات الجانبیة المحتملة&quot;).</p><p dir="RTL">من المھم أن تلاحظ أن المرضى الذین یعانون من الورم النقوي المتعدد ویعالجون ببومالیدوماید قد تتطور لدیھم أنواع إضافیة من السرطان، ولذلك ینبغي على طبیبك أن&nbsp; یقّیم منافع ومخاطر العلاج بعنایة عندما یوصف لك ھذا الدواء.&nbsp;</p><p>&nbsp;</p><p dir="RTL">في نھایة العلاج یجب أن تعید كل الكبسولات غیر المستعملة إلى الصیدلي.</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>الحمل ومنع الحمل والرضاعة الطبیعیة - معلومات للنساء والرجال&nbsp; </strong></p><p dir="RTL">یجب أن یتبع ما یلي كما جاء في برنامج<em>i-SECURE </em>&nbsp;لبومالیدوماید الخاص بمنع الحمل.&nbsp;</p><p dir="RTL">عند تناول إمنوفید ، لا یجب أن تصبح النساء حوامل أو الرجال&nbsp; آباء. ذلك لأنھ من المتوقع لبومالیدوماید أن یؤذي الطفلالذي لم یولد بعد. ینبغي علیك وعلى شریكك إستخدام أسالیب فعالة لمنع الحمل أثناء تناول ھذا الدواء .&nbsp;</p><p dir="RTL"><strong>النساء&nbsp; </strong></p><p dir="RTL">لا تتناولي إمنوفید إذا كنت حاملاحاملاً، أو تعتقدي أنك قد تكوني حاملاحاملاً أو تخططي لتصبحي حامًلاً. ذلك لأنھ من المتوقع لھذا الدواء أن یؤذي الطفل الذي لم یولد بعد. قبل البدء في العلاج، یجب علیك إبلاغ الطبیب إذا كنت قادرة على أن تصبحي حاملاحاملاً، حتى لو كنت تعتقدین أن ھذا أمر غیر مرجح.&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قادرة على أن تصبحي &nbsp;حاملاً:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یجب إستخدام طرق فعالة لمنع الحمل لمدة 4 أسابیع على الأقل قبل بدء العلاج، طوال الفترة الذي تتناولین فیھ العلاج ، ولغایة 4 أسابیع على الأقل بعد وقف العلاج. تحدثي مع طبیبك حول أفضل طریقة لمنع الحمل بالنسبة لك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في كل مرة یكتب لك فیھا الطبیب وصفة طبیة، سوف یضمن لك فھم التدابیر اللازمة التي یجب إتخاذھا لمنع الحمل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سیقوم الطبیب بترتیب إختبارات الحمل قبل العلاج، وكل 4 أسابیع على الأقل أثناء العلاج، و 4 أسابیع على الأقل بعد إنتھاء فترة العلاج.</p><p>&nbsp;</p><p dir="RTL"><strong>أمثلة لطرق فعالة في منع الحمل&nbsp; </strong></p><p dir="RTL">طرق فعالة للغایة:&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; جھاز داخل الرحم (IUD)&nbsp;</p><p dir="RTL">&nbsp;&nbsp; الھرمونیة (الغرسات الھرمونیة، نظام مطلق اللیفونورجیستریل داخل الرحم (IUS)، حقن مدخر أسیتات المیدروكسي بروجستیرون، البروجسترون مثبط التبویض &ndash; حبوب فقط مثل دیزوجیستریل)&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; عقد الأنبوب&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&amp;nbsأقل أثناء العلاج، و 4 أسابیع على الأقل بعد إنتھاء فترة العلاج.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبحت &nbsp;حاملاًعلى الرغم من إتخاذ التدابیر الوقائیة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یجب إیقاف العلاج فوراَ والتحدث مع طبیبك على الفور</p><p dir="RTL">الرضاعة الطبیعیة:&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL">من غیر المعروف ما إذا كان إمنوفید یمر في حلیب ثدي الإنسان. أخبري طبیبك إذا كنت ترضعین طفلك &nbsp; &nbsp;طبیعیًاأو تنوین إرضاعھ &nbsp;&nbsp;&nbsp; &nbsp;طبیعیًا. سوف ینصحك طبیبك إذا كان یجب وقف أو مواصلة الرضاعة الطبیعیة.&nbsp;</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>الرجال</strong>&nbsp;</p><p dir="RTL">یمر إمنوفید في السائل المنوي البشري.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت شریكة حیاتك حاملاًأو قادرة على أن تصبح حامًلاً، فیجب إستخدام الواقي الذكري طوال الوقت الذي تتناول فیھ العلاج ولمدة 7 أیام بعد إنتھاء العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبحت شریكة حیاتك حامًلاً أثناء تناولك إمنوفید، فأخبر طبیبك &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فورًا. یجب على شریكة حیاتك أن تخبرطبیبھا على الفور.</p><p dir="RTL">یجب أن لا تتبرع بسائل منوي أو حیوانات منویة أثناء العلاج ولمدة 7 أیام بعد إنتھاء العلاج.</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>التبرع بالدم وإختبارات الدم</strong>&nbsp;</p><p dir="RTL">یجب أن لا تتبرع بالدم خلال فترة العلاج ولمدة 7 أیام بعد إنتھاء العلاج.&nbsp;</p><p dir="RTL">ستجرى لك إختبارات دم عادیة قبل وأثناء العلاج بإمنوفید. ذلك لأن الدواء قد یسبب إ&nbsp;&nbsp; نخفاضًافي عدد خلایا الدم التي تساعد على مكافحة العدوى (الخلایا البیضاء) وفي عدد الخلایا التي تساعد على وقف النزیف (الصفائح الدمویة) .&nbsp;</p><p>&nbsp;</p><p dir="RTL">سیطلب منك طبیبك أن یجرى لك فحص دم:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل العلاج</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل أسبوع لأول 8 أسابیع من العلاج</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; على الأقل كل شھر بعد ذلك طالما كنت تتناول إمنوفید.</p><p dir="RTL">ونتیجة لھذه الاختبارات، قد یغیر طبیبك جرعة إمنوفید أو وقف العلاج. یمكن للطبیب أیضااً تغییر الجرعة أو إیقاف الدواءبسبب صحتك العامة.&nbsp;&nbsp;</p><p dir="RTL"><strong>الأطفال والمراھقین</strong>&nbsp;</p><p dir="RTL">لا ینصح بتناول إمنوفید من قبل الأطفال والشباب الذین ھم دون سن 18 عاماً.</p><p dir="RTL"><strong>الأدویة الأخرى و إمنوفید</strong>&nbsp;</p><p dir="RTL">أخبر طبیبك أو الصیدلي أو الممرضة إذا كنت تتناول، أو تناولت &nbsp;&nbsp; &nbsp;مؤخرًاأو قد تتناول أي أدویة أخرى. ذلك لأن إمنوفیدیمكن أن یؤثر على الطریقة التي تعمل بھا بعض الأدویة الأخرى. یمكن أن تؤثر أیضااً بعض الأدویة الأخرى على الطریقة التي یعمل بھا إمنوفید.&nbsp;</p><p>&nbsp;</p><p dir="RTL">على وجھ الخصوص، أخبر طبیبك أو الصیدلي أو الممرضة قبل تناول إمنوفید إذا كنت تتناول أي من الأدویة التالیة:&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الفطریات مثل كیتاكونازول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحیویة (على سبیل المثال سیبروفلوكساسین، إینوكساسین)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الإكتئاب مثل فلوفوكسامین.</p><p dir="RTL"><strong>القیادة وإستخدام المكائن</strong>&nbsp;</p><p dir="RTL">بعض الناس یشعرون بالتعب والدوار والإغماء، والإرتباك أو أقل إنتباھااً عند تناول إمنوفید. إذا حدث ھذا لك، لا تقود أو تشغل آلات أو مكائن.</p><p dir="RTL">یحتوي إیمنوفید على الصودیوم&nbsp;</p><p dir="RTL">یحتوي ھذا الدواء على أقل من 1 ملیمول من الصودیوم( 23 ملغ) لكل كبسولة ، لذلك فھو یعتبر أس اسًا خالًیًاً من الصودیوم.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الإكتئاب مثل فلوفوكسامین.</p><p>&nbsp;</p><p dir="RTL"><strong>القیادة وإستخدام المكائن</strong>&nbsp;</p><p dir="RTL">بعض الناس یشعرون بالتعب والدوار والإغماء، والإرتباك أو أقل إنتباھااً عند تناول إمنوفید. إذا حدث ھذا لك، لا تقود أو تشغل آلات أو مكائن.</p><p dir="RTL">یحتوي إیمنوفید على الصودیوم&nbsp;</p><p dir="RTL">یحتوي ھذا الدواء على أقل من 1 ملیمول من الصودیوم( 23 ملغ) لكل كبسولة ، لذلك فھو یعتبر أس اسًا خالًیًاً من الصودیوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">یجب أن یعطى إمنوفید لك من قبل طبیب من ذوي الخبرة في علاج الورم النقوي المتعدد.&nbsp;</p><p dir="RTL">دائمااً خذ أدویتك تمامااً كما أخبرك طبیبك بذلك. تحقق من طبیبك أو الصیدلي أو الممرضة إذا لم تكن متأكداً.</p><p dir="RTL">متى تأخذ إمنوفید مع الأدویة الأخرى&nbsp;</p><p>&nbsp;</p><p dir="RTL">إمنوفید مع بورتیزومیب ودیكسامیثازون&nbsp;</p><p dir="RTL">&bull;&nbsp; انظر المنشورات التي تأتي مع بورتیزومیب ودیكسامیثازون لمزید من المعلومات حول استخدامھا وآثارھا.&nbsp;</p><p dir="RTL">&bull;&nbsp; یؤخذ إمنوفید، بورتیزومیب و دیكسامیثازون في &quot;دورات العلاج&quot;. تستمر كل دورة 21 یوًمًا( 3 أسابیع.)&nbsp;</p><p dir="RTL">&bull;&nbsp; انظر إلى الرسم البیاني أدناه لترى ما یجب القیام بھ في كل یوم من أیام دورة الثلاثة أسابیع:&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل یوم ، انظر إلى الرسم البیاني أدناه وابحث عن الیوم الصحیح لمعرفة الأدویة التي یجب تناولھا.&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في بعض الأیام ، تتناول جمیع الأدویة الثلاثة ، في بعض الأیام<!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span> SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_94614" o:spid="_x0000_s1026"
 style='width:3.35pt;height:14.15pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_203651" o:spid="_x0000_s1027" style='position:absolute;
  width:42672;height:179832;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l42672,r,179832l,179832,,e" fillcolor="#fdfdfd" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,42672,179832"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="4" height="18" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
dir=LTR><v:shape id="_x0000_i1027" type="#_x0000_t75" style='width:3.35pt;
 height:14.15pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]-->دواءین أو واحد فقط، وفي بعض الأیام لا شيء على الإطلاق</p><p dir="RTL"><strong>إمن</strong>: إمنوفید;<strong> بور</strong>: بورتیزومیب;<strong> دیكس</strong>: دیكسامیثازون</p><p dir="RTL">دورة 1 إلى 8</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p dir="RTL">إسم الدواء&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>دیكس</strong>&nbsp;</p></td><td><p dir="RTL"><strong>بور</strong>&nbsp;</p></td><td><p dir="RTL"><strong>إمن</strong>&nbsp;</p></td><td><p dir="RTL">یوم&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٢</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٣</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٤</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٥</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٦</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٧</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٨</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٩</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٠</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١١</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٢</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٣</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٤</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٥</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٦</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٧</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٨</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٩</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٢٠</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; ٢١</p></td></tr></tbody></table><p dir="RTL">دورة 9 وما بعد</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p dir="RTL">إسم الدواء&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>دیكس</strong>&nbsp;</p></td><td><p dir="RTL"><strong>بور</strong>&nbsp;</p></td><td><p dir="RTL"><strong>إمن</strong>&nbsp;</p></td><td><p dir="RTL">یوم&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٢</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٣</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٤</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٥</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٦</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٧</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٨</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٩</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٠</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١١</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٢</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٣</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٤</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٥</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٦</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٧</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٨</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١٩</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٢٠</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٢١</p></td></tr></tbody></table><p dir="RTL">&bull;&nbsp; بعد الانتھاء من كل دورة 3 أسابیع، ابدأ دورة جدیدة.&nbsp;</p><p>&nbsp;</p><p dir="RTL">إمنوفید مع دیكسامیثازون فقط&nbsp;</p><p dir="RTL">&bull;&nbsp; انظر المنشور الذي یأتي مع دیكسامیثازون لمزید من المعلومات حول استخدامھ وآثاره.</p><p dir="RTL">یؤخذ إمنوفید و دیكسامیثازون في دورات علاجیة.&nbsp;</p><p dir="RTL">&nbsp;&nbsp; كل دورة تستمر 28&nbsp;&nbsp; یومًا( 4 أسابیع.)</p><p dir="RTL">&bull;&nbsp; انظر إلى الرسم البیاني أدناه لترى ما یجب أن تأخذ في كل یوم من أیام دورة الأربعة أسابیع:&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل یوم ، انظر إلى الرسم البیاني أدناه وابحث عن الیوم الصحیح لمعرفة الأدویة التي یجب تناولھا.&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في بعض الأیام، تأخذ الدواءین ، في بعض الأیام دواء واحد ، وفي بعض الأیام لا شيء على الإطلاق.</p><p dir="RTL"><strong>إمن</strong>: إمنوفید;<strong> دیكس</strong>: دیكسامیثازون</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p dir="RTL">إسم الدواء&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL"><strong>دیكس</strong>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p dir="RTL"><strong>إمن</strong>&nbsp;</p></td><td><p dir="RTL">یوم&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ١</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٢</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; &radic;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp; ٣</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; &radic;</p></td><td colspan="2"><p>&nbsp; ٤&nbsp; &nbsp;&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; &radic;</p></td><td colspan="2"><p>&nbsp; ٥</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; &radic;</p></td><td colspan="2"><p>&nbsp; ٦</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2" rowspan="15"><p>&radic;</p></td><td colspan="2"><p>&nbsp; ٧</p></td></tr><tr><td><p>&nbsp; &radic;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2"><p>&nbsp; ٨</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;&nbsp;&nbsp;</p></td><td colspan="2"><p>&nbsp; ٩</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2"><p>&nbsp; ١٠</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2"><p>&nbsp; ١١</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2"><p>&nbsp; ١٢</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2"><p>&nbsp; ١٣</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; ١٤</p></td></tr><tr><td><p>&nbsp; &radic;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2"><p>&nbsp; ١٥</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2"><p>&nbsp; ١٦</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2"><p>&nbsp; ١٧</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2"><p>&nbsp; ١٨</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2"><p>&nbsp; ١٩</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2"><p>&nbsp; ٢٠</p></td></tr><tr><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2"><p>&nbsp; ٢١</p></td></tr><tr><td><p>&nbsp; &radic;</p></td><td colspan="2"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; ٢٢</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; ٢٣</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; ٢٤</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; ٢٥</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; ٢٦</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; ٢٧</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td><td colspan="2"><p>&nbsp; ٢٨</p></td></tr></tbody></table><p dir="RTL">&bull;&nbsp; بعد الانتھاء من كل دورة 4 أسابیع ، ابدأ دورة جدیدة.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL"><strong>الكمیة الممكن تناولھا من إمنوفید مع الأدویة الأخرى</strong>&nbsp; <strong>إمنوفید مع بورتیزومیب ودیكسامیثازون</strong>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدایة الموصى بھا من إمنوفید ھي 4 ملغم یومیاً .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدایة الموصى بھا من بورتیزومیب سیعمل بھا طبیبك واستنادا إلى طولك ووزنك (مساحة سطح الجسم 1.3ملغم /متر مربع).&nbsp;</p><p></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدایة الموصى بھا من الدیكسامیثازون ھي 20 ملغم في الیوم. ومع ذلك ، إذا كان عمرك أكثر من 75، فإن جرعة البدایة الموصى بھا ھي 10 ملغم یومًیًاً.</p><p>&nbsp;</p><p dir="RTL">إمنوفید مع دیكسامیثازون فقط&nbsp;</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بھا من إمنوفید ھي 4 ملغم یومیا.</p><p>&nbsp;</p><p dir="RTL">جرعة البدایة الموصى بھا من دیكسامیثازون ھي 40 ملغم یومیااً.&nbsp; ومع ذلك ، إذا كان عمرك أكثر من 75، فإن جرعة البدایة الموصى بھا ھي 20 ملغ یومًیًاً.&nbsp;</p><p dir="RTL">قد یحتاج طبیبك إلى تقلیل جرعة إمنوفید، بورتیزومیب أو دیكسامیثازون أو وقف واحد أو أكثر من ھذه الأدویة بناء على نتائج إختبارات الدم الخاصة بك، وحالتك العامة، إن الأدویة الأخرى التي تتناولھا (مثل سیبروفلوكساسین، إینوكساسینوفلوفوكسامین) وإذا ما كنت تواجھ تأثیرات جانبیة (وخاصة الطفح الجلدي أو الانتفاخ) من العلاج. إذا كنت تعاني من مشاكل في الكلى أو الكبد فسوف یتحقق طبیبك من حالتك بعنایة فائقة أثناء تناولك ھذا الدواء.&nbsp;</p><p dir="RTL"><strong>كیف تتناول إمنوفید&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكسر أو تفتح أو تمضغ الكبسولات. إذا ما لامس جلدك مسحوق إمنوفید من كبسولة مكسورة، إغسل الجلد فوراً وجیداً بالصابون والماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبلع الكبسولات بأكملھا، ویفضل مع الماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یمكنك أن تتناول الكبسولات إما مع أو بدون الطعام.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول إمنوفید في نفس الوقت تقریبااً كل یوم.</p><p>&nbsp;</p><p dir="RTL">لإخراج الكبسولة من التغلیف اضغط على أحد جوانب الكبسولة فقط لإخراجھا من الرقاقة المعدنیة .&nbsp;</p><p dir="RTL">لا تضعط بقوة على الكبسولة من الوسط فقد تنكسر.&nbsp;</p><p>&nbsp;</p><p><img alt="" width="609" height="802" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p dir="RTL">سیحدد لك الطبیب كیفیة ومواعید تناول إمنوفید وإذا كانت لدیك مشاكل في الكلى تقوم بعملیة الغسیل الكلوي.&nbsp;</p><p dir="RTL"><strong>مدة العلاج بإمنوفید</strong>&nbsp;</p><p dir="RTL">یجب أن تستمر دورات العلاج حتى یخبرك طبیبك بالتوقف.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تناولت إمنوفید أكثر مما یجب</strong>&nbsp;</p><p dir="RTL">إذا تناولت إمنوفید أكثر مما یجب فتحدث إلى الطبیب أو إذھب إلى المستشفى على الفور. خذ علبة الدواء معك.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسیت أن تتناول إمنوفید </strong>&nbsp;&nbsp;</p><p dir="RTL">إذا نسیت أن تتناول إمنوفید في یوم ما عندما یجب أن تتناولھ، فتناول الكبسولة القادمة كالمعتاد في الیوم التالي. لا تزید عدد الكبسولات التي تتناولھا للتعویض عن عدم تناولك إمنوفید في الیوم السابق.&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا كان لدیك أي أسئلة أخرى عن إستعمال ھذا الدواء، فإسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جمیع الأدویة، یمكن لھذا الدواء أن یسبب تأثیرات جانبیة، وإن لم تحصل للجمیع.&nbsp;</p><p dir="RTL">التأثیرات الجانبیة الخطیرة&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول إمنوفید ومراجعة الطبیب على الفور، إذا لاحظت أي من التأثیرات الجانبیة الخطیرة التالیة: - قد تحتاج إلى علاج طبي عاجل:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى، قشعریرة، إلتھاب الحلق، السعال، قرحة الفم أو أي علامات أخرى للعدوى (نتیجة لعدد أقل من خلایا الدم البیضاء، التي تكافح العدوى.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزیف أو كدمات من دون سبب،&nbsp; بما في ذلك نزیف الأنف ونزیف الأمعاء أو المعدة (نتیجة للتأثیرات على خلایا دمویة تسمى &#39;الصفائح الدمویة.)&#39;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنفس سریع ،نبض سریع ،حمى وقشعریرة ، تبول القلیل من البول إلى عدم التبول ، الغثیان والقيء ،الارتباك ،فقدان الوعي (بسبب إلتھاب في الدم یسمى الإنتان أو الصدمة الإنتانیة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسھال شدید ومستمر أو دموي (ربما مع ألم في المعدة أو حمى) تسببھ بكتیریا تسمى المطثیات العسیرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر، أو ألم في الساق وتورم، وخاصة في أسفل الساق أو الشظیة (التي تسببھا الجلطات الدمویة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضیق في التنفس (من عدوى خطیرة في الصدر، التھاب الرئة، قصور القلب أو تجلط الدم.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجھ والشفتین واللسان والحلق، والتي قد تسبب صعوبة في التنفس (نظرا لنوع خطیر من الحساسیة یسمى الوذمة الوعائیة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع سرطان الجلد (سرطان الخلایا الحرشفیة وسرطان الخلایا القاعدیة)، التي قد تسبب تغیرات في مظھر بشرتك أو أورام بالجلد. إذا لاحظت أي تغییرات على بشرتك عند تناول إمنوفید، أخبر طبیبك في أسرع وقت ممكن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكرار الإصابة بالتھاب الكبد الفیروسي بي، الذي یمكن أن&nbsp; یسبب إصفراًرًا بالجلد والعینین، لون البول البني الداكن ،آلام بالجانب الأیمن من البطن ،الحمى والغثیان أوالشعور بالمرض. أخبر طبیبك فوًرًا إذا لاحظت أي من ھذه الأعراض.</p><p dir="RTL"><strong>توقف عن تناول إمنوفید واستشر الطبیب على الفور </strong>إذا لاحظت أي من الآثار الجانبیة الخطیرة المذكورة أعلاه - قد تحتاج إلى علاج طبي عاجل.</p><p dir="RTL"><strong>التأثیرات الجانبیة الأخرى</strong>&nbsp;</p><p dir="RTL"><strong>شائعة&nbsp; جدًا</strong>: قد تؤثر على أكثر من 1 على 10 أشخاص&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضیق في التنفس (الزلة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھابات الرئتین (الالتھاب الرئوي والتھاب الشعب الھوائیة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھابات الأنف ،الجیوب الأنفیة والحنجرة التي تسببھا البكتیریا أو الفیروسات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض خلایا الدم الحمراء ، والتي قد تسبب فقر الدم مما یؤدي إلى التعب والضعف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستویات الدم من البوتاسیوم (نقص بوتاسیوم الدم) ، والذي قد یسبب الضعف ، تشنجات العضلات ، آلام العضلات ، الخفقان ، وخز أو تنمیل ، ضیق التنفس ، وتغیرات المزاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستویات السكر في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشھیة.إمساك، إسھال أو الغثیان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أن تكون مریًضًا (القيء.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في الطاقة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم أو البقاء نائما.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة ، الرعشھ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج العضلات و. ضعف العضلات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العظام وآلام الظھر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنمیل ،وخز أو حرقان في الجلد ، آلام في الیدین أو القدمین (إعتلال عصبي حسي حركي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجسم، بما في ذلك تورم في الذراعین أو الساقین.</p><p>&nbsp;</p><p dir="RTL"><strong>الشائعة</strong>: قد تؤثر على ما یصل إلى 1 على 10 أشخاص&nbsp; &nbsp;&nbsp; السقوط&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزیف داخل الجمجمة&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض القدرة على الحركة أو الشعور (الإحساس) في یدیك ،ذراعیك ،قدمیك وساقیك بسبب تلف الأعصاب( إعتلال عصبي حسي حركي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنمیل ، حكة ، وشعور دبابیس وإبر على جلدك( مََذَلَ).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوار في رأسك ، مما یجعل من الصعب الوقوف والتحرك بشكل طبیعي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم ناتج عن السوائل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (الطفح الجلدي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ِھِْرْبِ ٌسٌِ نُطُا ِقِيِّ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب وعدم انتظامھا (الرجفان الأذیني).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات القلبیة (ألم في الصدر یمتد إلى الذراعین والرقبة والفك، والشعور بالتعرق وصعوبة التنفس، والشعور بالغثیانأو التقیؤ).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر ، التھاب في الصدر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة ضغط الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلایا الدم الحمراء والبیضاء والصفائح الدمویة في نفس الوقت (قلة الكریات الشاملة والتي سوف تجعلكأكثر عرضة للنزیف والكدمات. قد تشعر بالتعب والضعف، وضیق التنفس وقد تكون أكثر عرضة للإصابة بالالتھاب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلایا الدم البیضاء (نوع واحد من خلایا الدم البیضاء) غالبًا ما یكون ناتًجًا عن إلتھاب (اللمفاویات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستویات المغنیسیوم في الدم (نقص مغنیسیوم الدم) ، والذي قد یسبب التعب ، الضعف العام ، تشنجات العضلات ، إنزعاج ، وقد یؤدي إلى انخفاض مستویات الكالسیوم في الدم (نقص كلس الدم) ، مما قد یؤدي إلى تنمیل أو وخز في الیدین أو القدمین أو الشفاه ، تشنجات العضلات ، ضعف العضلات ،الدوار والارتباك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الدم من الفوسفات (نقص فوسفات الدم) ، والذي قد یسبب ضعف العضلات و<!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span> SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_92821" o:spid="_x0000_s1026"
 style='width:3.35pt;height:14.15pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_208599" o:spid="_x0000_s1027" style='position:absolute;
  width:42672;height:179832;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l42672,r,179832l,179832,,e" fillcolor="#fdfdfd" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,42672,179832"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="5" height="19" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:3.35pt;
 height:14.15pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]-->الإنزعاج أو الارتباك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الكالسیوم في الدم (فرط كالسیوم الدم) ، مما قد یؤدي إلى تباطؤ ردود الفعل وضعف العضلات الھیكلیة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستویات عالیة من البوتاسیوم في الدم، الذي قد یسبب ضربات قلب غیر طبیعیة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستویات منخفضة من الصودیوم في الدم، الذي قد یسبب التعب والإرتباك، وإرتعاش العضلات، ونوبات (نوبات صرع) أو غیبوبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستویات حمض الیوریك في الدم، ما قد یسبب نوع من التھاب المفاصل یسمى النقرس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم ، والذي قد یسبب الدوخة أو الإغماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض تشبھ الانفلونزا (الانفلونزا.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة أو جفاف الفم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغییرات في طریقة تذوق الأشیاء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن ، تورم في البطن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإرتباك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإحباط (المزاج المكتئب.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي، الاغماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تَ َغَیُّ َمُّ&nbsp; في عینك (كاتاراكت).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على التبول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج إختبار غیر طبیعیة للكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتھاب المسالك البولیة ، والتي قد تسبب إحساًسًاً حارًقًاً عند مرور البول ، أو الحاجة إلى التبول كثیًرًا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الحوض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن.</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>غیر شائعة</strong>: قد تؤثر على ما یصل إلى 1 على 100 شخص&nbsp; &nbsp;&nbsp; السكتة الدماغیة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب الكبد (الفیروسي) والذي یمكن أن یسبب حكة بالجلد، إصفرار الجلد وبیاض العینین (الیرقان)،&nbsp; لون البرازالشاحب، ولون البول الداكن وآلام في البطن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انھیار الخلایا السرطانیة مما یؤدي إلى سریان المركبات السامة في مجرى الدم (متلازمة انحلال الورم). ما قد یؤديإلى مشاكل في الكلى.</p><p dir="RTL">غیر معروفة (لا یمكن تقدیر التر دّ من البیانات المتاحة:)&nbsp;</p><p dir="RTL">&bull; الطفح الجلدي المنتشر، وارتفاع درجة حرارة الجسم، &nbsp;&nbsp; &nbsp;وتضخّم الغدد اللیمفاویة وغیرھا من أعضاء الجسم (التفاعلات الدوائیة مع فرط الحمضات والأعراض الجھازیة التي تعرف أیض ًاباسم متلازمة فروسیة أو مخاض فرط الحساسیة للمخدرات، أو انحلال البشرة النخري السمي أو متلازمة ستیفنز جونسون). إذا قمت بتطویر ھذه الأعراض ،علیك التوقف عن استخدام pomalidomide والاتصال بطبیبك أو الحصول على الرعایة الطبیة على الفور .أنظر&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أیضًاالجزء 2.<strong>الإبلاغ عن التأثیرات الجانبیة</strong>&nbsp;</p><p>اذا حصلت لك أي تأثیرات جانبیة، فتحدث مع طبیبك أو الصیدلي أو الممرضة. وھذا یشمل أي تأثیرات جانبیة محتملة من غیر المدرجة في ھذه النشرة. بإبلاغك عن التأثیرات الجانبیة یمكنك أن تساعد على توفیر مزید من المعلومات حول سلامةھذا الدواء</p><p>ن التأثیرات الجانبیة یمكنك أن تساعد على توفیر مزید من المعلومات حول سلامةھذا الدواء</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إحفظ ھذا الدواء بعیداً عن نظر ومتناول الأطفال.&nbsp;</p><p dir="RTL">یخزن تحت أقل من 30 درجة مئویة.&nbsp;</p><p dir="RTL">لا تستعمل ھذا الدواء بعد إنتھاء تاریخ الصلاحیة المبین على الاصق والكارتون بعدEXP . تاریخ إنتھاء الصلاحیة یشیر إلى الیوم الأخیر من ذلك الشھر.&nbsp;</p><p dir="RTL">لا تستعمل إمنوفید إذا لاحظت أي ضرر أو علامات عبث في علبة الدواء .&nbsp;</p><p dir="RTL">لا تتخلص من أي أدویة عن طریق میاه الصرف الصحي أو النفایات المنزلیة. یجب أن یعاد أي دواء غیر مستعمل إلىالصیدلي في نھایة العلاج. وسوف تساعد ھذه التدابیر على حمایة البیئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن المادة الفعالة ھي بومالیدوماید</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى ھي مانیتول(E421)، ونشاء،&nbsp; بریجیلاتینایزد وفومارات ستیاریل الصودیوم.</p><p dir="RTL">إمنوفید 1 ملغم كبسولة صلبة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل كبسولة تحتوي على 1 ملغم من بومالیدوماید.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي غلاف الكبسولة على: الجیلاتین، ثاني أوكسید التیتانیوم(E171) ، إندیجوتین (E132)، أوكسید الحدید الأصفر</p><p dir="RTL">(E172) والحبر الأبیض والأسود.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي حبر الطباعة على: صمغ اللك، ثاني أوكسید التیتانیوم( E171)، سیمیثیكون، جلایكول البروبیلین( E1520)، ھیدروكسید الأمونیوم( E527) (حبر أبیض) صمغ اللك ، أوكسید الحدید الأسود( E172)، غلیكول البروبیلین (E1520) وھیدروكسید الأمونیوم( E527) (حبر أسود.)</p><p dir="RTL">إمنوفید 2 ملغم كبسولة صلبة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل كبسولة تحتوي على 2 ملغم من بومالیدوماید.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي غلاف الكبسولة على: الجیلاتین، ثاني أوكسید التیتانیوم(E171) ، إندیجوتین (E132)، أوكسید الحدید الأصفر</p><p dir="RTL">(E172)، إریثروسین( E127) والحبر الأبیض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي حبر الطباعة على: الحبر الأبیض ،صمغ اللك، ثاني أوكسید التیتانیوم( E171)، سیمیثیكون، غلیكول البروبیلین( E1520) وھیدروكسید الأمونیوم( E527).</p><p>&nbsp;</p><p dir="RTL">إمنوفید 3 ملغم كبسولة صلبة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل كبسولة تحتوي على 3 ملغم من بومالیدوماید.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي غلاف الكبسولة على: الجیلاتین، ثاني أوكسید التیتانیوم (E171)، إندیجوتین (E132)، أوكسید الحدید الأصفر</p><p dir="RTL">(E172) والحبر الأبیض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي حبر الطباعة على: الحبر الأبیض ،صمغ اللك، ثاني أوكسید التیتانیوم( E171)، سیمیثیكون، غلیكول البروبیلین( E1520) وھیدروكسید الأمونیوم( E527).</p><p>&nbsp;</p><p dir="RTL">إمنوفید 4 ملغم كبسولة صلبة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل كبسولة تحتوي على 4 ملغم من بومالیدوماید.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي غلاف الكبسولة على: الجیلاتین، ثاني أكسید التیتانیوم (E171)، إندیجوتین (E132)، الأزرق اللامعFCF</p><p dir="RTL">(E133)، والحبر الأبیض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي حبر الطباعة على: الحبر الأبیض، صمغ اللك، ثاني أوكسید التیتانیوم (E171)، سیمیثیكون، غلیكول البروبیلین (E1520) وھیدروكسید الأمونیوم (E527).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما ھو شكل إمنوفید وما ھي محتویات العلبة</strong>&nbsp;</p><p dir="RTL">إمنوفید 1 ملغم كبسولة صلبة: غطاء أزرق داكن غیر شفاف وجسم أصفر غیر شفاف، مكتوب علیھا&ldquo;POML 1 mg&rdquo; .&nbsp;</p><p dir="RTL">إمنوفید 2 ملغم كبسولة صلبة: غطاء أزرق داكن غیر شفاف وجسم برتقالي غیر شفاف، مكتوب علیھا&ldquo;POML 2 mg&rdquo; .</p><p dir="RTL">إمنوفید 3 ملغم كبسولة صلبة: غطاء أزرق داكن غیر شفاف وجسم أخضر غیر شفاف، مكتوب علیھا&ldquo;POML 3 mg&rdquo; .</p><p dir="RTL">إمنوفید 4 ملغم كبسولة صلبة: غطاء أزرق داكن غیر شفاف وجسم أزرق غیر شفاف، مكتوب علیھا&ldquo;POML 4 mg&rdquo; .</p><p>&nbsp;</p><p dir="RTL">كل علبة تحتوي على 21 كبسولة (3 نفطات 7 x كبسولات).&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="LTR">Celgene Europe B.V., Netherlands <strong>الشركة المالكة لحق التسویق</strong></p><p dir="LTR"><strong>&nbsp; </strong>Celgene International Sarl, Boudry, Switzerland<strong> :</strong><strong>المصّنّعّ</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم الموافقة على ھذه النشرة بتاریخ أغسطس 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Imnovid 1 mg hard capsules Imnovid 2 mg hard capsules Imnovid 3 mg hard capsules Imnovid 4 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Imnovid 1 mg hard capsules
Each hard capsule contains 1 mg of pomalidomide.
Imnovid 2 mg hard capsules
Each hard capsule contains 2 mg of pomalidomide.
Imnovid 3 mg hard capsules
Each hard capsule contains 3 mg of pomalidomide.
Imnovid 4 mg hard capsules
Each hard capsule contains 4 mg of pomalidomide. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.
Imnovid 1 mg hard capsule:
Dark blue opaque cap and yellow opaque body, imprinted “POML” in white ink and “1 mg” in black ink, size 3 gelatin hard capsule.
Imnovid 2 mg hard capsules
Dark blue opaque cap and orange opaque body, imprinted “POML 2 mg” in white ink, size 1 gelatin hard capsule.
Imnovid 3 mg hard capsules
Dark blue opaque cap and green opaque body, imprinted “POML 3 mg” in white ink, size 1 gelatin hard capsule.
Imnovid 4 mg hard capsules
Dark blue opaque cap and blue opaque body, imprinted “POML 4 mg” in white ink, size 1 gelatin hard capsule.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.</p><p>Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment must be initiated and monitored under the supervision of physicians experienced in the management of multiple myeloma.</p><p>Dosing is continued or modified based upon clinical and laboratory findings (see section 4.4).</p><p>Posology</p><p> Pomalidomide in combination with bortezomib and dexamethasone</p><p>The recommended starting dose of Imnovid is 4 mg orally once daily on Days 1 to 14 of repeated 21-day cycles.</p><p>Pomalidomide is administered in combination with bortezomib and dexamethasone, as shown in Table 1. The recommended starting dose of bortezomib is 1.3 mg/m<sup>2 </sup>intravenous or subcutaneous once daily, on the days shown in Table 1. The recommended dose of dexamethasone is 20 mg orally once daily, on the days shown in Table 1.</p><p>Treatment with pomalidomide combined with bortezomib and dexamethasone should be given until disease progression or until unacceptable toxicity occurs.</p><p>Table 1. Recommended dosing scheme for Imnovid in combination with bortezomib and dexamethasone</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Cycle 1-8</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="14"><p>Day (of 21-day cycle)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>1</p></td><td><p>2</p></td><td><p>3</p></td><td><p>4</p></td><td><p>5</p></td><td><p>6</p></td><td><p>7</p></td><td><p>8</p></td><td><p>9</p></td><td><p>10</p></td><td><p>11</p></td><td><p>12</p></td><td><p>13</p></td><td><p>14</p></td><td><p>15</p></td><td><p>16</p></td><td><p>17</p></td><td><p>18</p></td><td><p>19</p></td><td><p>20</p></td><td><p>21</p></td></tr><tr><td><p>Pomalidomide (4 mg)</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Bortezomib (1.3 mg/m<sup>2</sup>)</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Dexamethasone (20 mg) *</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Cycle 9 onwards</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td colspan="14"><p>Day (of 21-day cycle)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>1</p></td><td><p>2</p></td><td><p>3</p></td><td><p>4</p></td><td><p>5</p></td><td><p>6</p></td><td><p>7</p></td><td><p>8</p></td><td><p>9</p></td><td><p>10</p></td><td><p>11</p></td><td><p>12</p></td><td><p>13</p></td><td><p>14</p></td><td><p>15</p></td><td><p>16</p></td><td><p>17</p></td><td><p>18</p></td><td><p>19</p></td><td><p>20</p></td><td><p>21</p></td></tr><tr><td><p>Pomalidomide (4 mg)</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Bortezomib (1.3 mg/m<sup>2</sup>)</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Dexamethasone (20 mg) *</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&bull;</p></td><td><p>&bull;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>* For patients &gt; 75 years of age, see Special populations.</p><p><em><u>Pomalidomide dose modification or interruption</u></em></p><p>To initiate a new cycle of pomalidomide, the neutrophil count must be  1 x 10<sup>9</sup>/l and the platelet count must be  50 x 10<sup>9</sup>/l.</p><p>Instructions on dose interruptions or reductions for pomalidomide related adverse reactions are outlined in the Table 2 and dose levels are defined in Table 3 below:</p><p>Table 2. Pomalidomide dose modification instructions<sup>&infin;</sup></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Toxicity</strong></p></td><td><p><strong>Dose modification</strong></p></td></tr><tr><td><p><strong><u>Neutropenia</u></strong>*</p><p>ANC** &lt; 0.5 x 10<sup>9</sup>/l or febrile neutropenia</p><p>(fever &ge;38.5&deg;C and ANC &lt;1 x 10<sup>9</sup>/l)</p></td><td><p>Interrupt pomalidomide treatment for remainder of cycle. Follow CBC*** weekly.</p></td></tr><tr><td><p>ANC return to &ge; 1 x 10<sup>9</sup>/l</p></td><td><p>Resume pomalidomide treatment at one dose level lower than previous dose.</p></td></tr><tr><td><p>For each subsequent drop &lt; 0.5 x 10<sup>9</sup>/l</p></td><td><p>Interrupt pomalidomide treatment.</p></td></tr><tr><td><p>ANC return to &ge; 1 x 10<sup>9</sup>/l</p></td><td><p>Resume pomalidomide treatment at one dose level lower than the previous dose.</p></td></tr><tr><td><p><strong><u>Thrombocytopenia</u></strong></p><p>Platelet count &lt; 25 x 10<sup>9</sup>/l</p></td><td><p>Interrupt pomalidomide treatment for remainder of cycle. Follow CBC*** weekly.</p></td></tr><tr><td><p>Platelet count return to &ge; 50 x 10<sup>9</sup>/l</p></td><td><p>Resume pomalidomide treatment at one dose level lower than previous dose.</p></td></tr><tr><td><p>For each subsequent drop &lt; 25 x 10<sup>9</sup>/l</p></td><td><p>Interrupt pomalidomide treatment.</p></td></tr><tr><td><p>Platelet count return to &ge; 50 x 10<sup>9</sup>/l</p></td><td><p>Resume pomalidomide treatment at one dose level lower than the previous dose.</p></td></tr><tr><td><p><strong><u>Rash</u></strong></p><p>Rash = Grade 2-3</p></td><td><p>Consider dose interruption or discontinuation of pomalidomide treatment.</p></td></tr><tr><td><p>Rash = Grade 4 or blistering (including angioedema, exfoliative or bullous rash or if Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN) or Drug Reaction with Eosinophilia and Systemic Symptoms</p><p>(DRESS) is suspected)</p></td><td><p>Permanently discontinue treatment (see section 4.4).</p></td></tr><tr><td><p>Other<br />Other &ge; Grade 3 pomalidomide-related adverse</p><p>events</p></td><td><p>Interrupt pomalidomide treatment for remainder of cycle. Resume at one dose level lower than previous dose at next cycle (adverse event must be resolved or improved to &le; Grade 2 before restarting dosing).</p></td></tr></tbody></table><p><strong>&infin; </strong>Dose modification instructions in this table are applicable to pomalidomide in combination with bortezomib and dexamethasone and to pomalidomide in combination with dexamethasone.</p><p>*In case of neutropenia, the physician should consider the use of growth factors. **ANC &ndash; Absolute Neutrophil Count; ***CBC &ndash; Complete Blood Count.</p><p>Table 3. Pomalidomide dose reduction&infin;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Dose level</strong></p></td><td><p><strong>Oral pomalidomide dose</strong></p></td></tr><tr><td><p>Starting dose</p></td><td><p>4 mg</p></td></tr><tr><td><p>Dose level -1</p></td><td><p>3 mg</p></td></tr><tr><td><p>Dose level -2</p></td><td><p>2 mg</p></td></tr><tr><td><p>Dose level -3</p></td><td><p>1 mg</p></td></tr></tbody></table><p><strong><sup>&infin;</sup></strong>Dose reduction in this table is applicable to pomalidomide in combination with bortezomib and dexamethasone and to pomalidomide in combination with dexamethasone.</p><p>If adverse reactions occur after dose reductions to 1 mg, then the medicinal product should be discontinued<em>.</em></p><p>Strong CYP1A2 inhibitors</p><p>If strong inhibitors of CYP1A2 (e.g. ciprofloxacin, enoxacin and fluvoxamine) are co-administered with pomalidomide, reduce the dose of pomalidomide by 50% (see sections 4.5 and 5.2).</p><p>Bortezomib dose modification or interruption</p><p>For instructions on dose interruptions or reductions for bortezomib related adverse reactions, physicians should refer to bortezomib Summary of Product Characteristics (SmPC).</p><p>Dexamethasone dose modification or interruption</p><p>Instructions on dose interruptions or reductions for low-dose dexamethasone related adverse reactions are outlined in Tables 4 and 5 below. However, dose interruption or resumption decisions are at the physician&rsquo;s discretion per Summary of Product Characteristics (SmPC). <strong>Table 4. Dexamethasone dose modification instructions</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Toxicity</strong></p></td><td><p><strong>Dose Modification</strong></p></td></tr><tr><td><p>Dyspepsia = Grade 1-2</p></td><td><p>Maintain dose and treat with histamine (H<sub>2</sub>) blockers or equivalent. Decrease by one dose level if symptoms persist.</p></td></tr><tr><td><p>Dyspepsia &ge; Grade 3</p></td><td><p>Interrupt dose until symptoms are controlled. Add H<sub>2 </sub>blocker or equivalent and resume at one dose level lower than previous dose.</p></td></tr><tr><td><p>Oedema &ge; Grade 3</p></td><td><p>Use diuretics as needed and decrease dose by one dose level.</p></td></tr><tr><td><p>Confusion or mood alteration &ge; Grade 2</p></td><td><p>Interrupt dose until symptoms resolve. Resume at one dose level lower than previous dose.</p></td></tr><tr><td><p>Muscle weakness &ge; Grade 2</p></td><td><p>Interrupt dose until muscle weakness &le; Grade 1.</p><p>Resume at one dose level lower than previous dose.</p></td></tr><tr><td><p><strong>Toxicity</strong></p></td><td><p><strong>Dose Modification</strong></p></td></tr><tr><td><p>Hyperglycaemia &ge; Grade 3</p></td><td><p>Decrease dose by one dose level. Treat with insulin or oral hypoglycaemic agents as needed.</p></td></tr><tr><td><p>Acute pancreatitis</p></td><td><p>Discontinue dexamethasone from treatment regimen.</p></td></tr><tr><td><p>Other &ge; Grade 3 dexamethasone-related adverse events</p></td><td><p>Stop dexamethasone dosing until the adverse event resolves to &le; Grade 2. Resume at one dose level lower than previous dose.</p></td></tr></tbody></table><p>If recovery from toxicities is prolonged beyond 14 days, then the dose of dexamethasone will be resumed at one dose level lower than the previous dose.</p><p>Table 5. Dexamethasone dose reduction</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Dose Level</strong></p></td><td><p><strong>&le; 75 years old</strong></p><p><strong>Dose (Cycle 1-8: Days 1, 2, 4, 5, 8, 9, 11, </strong></p><p><strong>12 of a 21-day cycle</strong></p><p><strong>Cycle &ge; 9: Days 1, 2, 8, 9 of a 21-day cycle)</strong></p></td><td><p><strong>&gt; 75 years old</strong></p><p><strong>Dose (Cycle 1-8: Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21-day cycle</strong></p><p><strong>Cycle &ge; 9: Days 1, 2, 8, 9 of a 21-day cycle)</strong></p></td></tr><tr><td><p>Starting Dose</p></td><td><p>20 mg</p></td><td><p>10 mg</p></td></tr><tr><td><p>Dose Level -1</p></td><td><p>12 mg</p></td><td><p>6 mg</p></td></tr><tr><td><p>Dose Level -2</p></td><td><p>8 mg</p></td><td><p>4 mg</p></td></tr></tbody></table><p>Dexamethasone should be discontinued if the patient is unable to tolerate 8 mg if &le; 75 years old or 4 mg if <strong>&gt; </strong>75 years old.</p><p>In case of permanent discontinuation of any component of the treatment regimen, continuation of the remaining medicinal products is at the physician&rsquo;s discretion.</p><p> <em>Pomalidomide in combination with dexamethasone</em></p><p>The recommended starting dose of Imnovid is 4 mg orally once daily on Days 1 to 21 of each 28-day cycle.</p><p>The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28day cycle.</p><p>Treatment with pomalidomide combined with dexamethasone should be given until disease progression or until unacceptable toxicity occurs.</p><p><em>Pomalidomide dose modification or interruption</em></p><p>Instructions for dose interruptions or reductions for pomalidomide related adverse reactions are outlined in Table 2 and 3.</p><p><em>Dexamethasone dose modification or interruption</em></p><p>Instructions for dose modification for dexamethasone related adverse reactions are outlined in Table 4.</p><p>Instructions for dose reduction for dexamethasone related adverse reactions are outlined in Table 6 below. However, dose interruption / resumption decisions are at physician&rsquo;s discretion per the current Summary of Product Characteristics (SmPC).</p><p>Table 6. Dexamethasone dose reduction</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Dose Level</strong></p></td><td><p><strong>&le; 75 years old</strong></p><p><strong>Days 1, 8, 15 and 22 of each 28-day cycle</strong></p></td><td><p><strong>&gt; 75 years old</strong></p><p><strong>Days 1, 8, 15 and 22 of each 28-day&nbsp; cycle</strong></p></td></tr><tr><td><p>Starting Dose</p></td><td><p>40 mg</p></td><td><p>20 mg</p></td></tr><tr><td><p>Dose Level -1</p></td><td><p>20 mg</p></td><td><p>12 mg</p></td></tr><tr><td><p>Dose Level -2</p></td><td><p>10mg</p></td><td><p>8 mg</p></td></tr></tbody></table><p>Dexamethasone should be discontinued if the patient is unable to tolerate 10 mg if &le; 75 years old or 8 mg if <strong>&gt; </strong>75 years old.</p><p>Special populations</p><p>Elderly</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with bortezomib and dexamethasone </em>No dose adjustment is required for pomalidomide.</p><p>For information on bortezomib given in combination with Imnovid, refer to the respective current SmPC.</p><p>For patients &gt;75 years of age, the starting dose of dexamethasone is:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For Cycles 1 to 8: 10 mg once daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle &nbsp;&nbsp; For Cycles 9 and onwards: 10 mg once daily on Days 1, 2, 8 and 9 of each 21-day cycle.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with dexamethasone </em>No dose adjustment is required for pomalidomide.</p><p>For patients &gt; 75 years of age, the starting dose of dexamethasone is:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 mg once daily on days 1, 8, 15 and 22 of each 28-day treatment cycle.</p><p>Hepatic impairment</p><p>Patients with serum total bilirubin &gt; 1.5 x ULN (upper limit of normal range) were excluded from clinical studies. Hepatic impairment has a modest effect on the pharmacokinetics of pomalidomide (see section 5.2). No adjustment of the starting dose of pomalidomide is required for patients with hepatic impairment as defined by the Child-Pugh criteria. However, patients with hepatic impairment should be carefully monitored for adverse reactions and dose reduction or interruption of pomalidomide should be used as needed.</p><p>Renal impairment</p><p>No dose adjustment of pomalidomide is required for patients with renal impairment. On haemodialysis days, patients should take their pomalidomide dose following haemodialysis.</p><p><em>Paediatric population</em></p><p><em>Outside its authorised indications, pomalidomide<br />has been studied in children aged 4 to 18 years<br />with recurent or progressive brain tumours,<br />however the results of studies did not allow to<br />conclude that the benefits of such use outweigh<br />the risks. Currently available data are described in<br />section 4.8, 5.1 and 5.2</em></p><p>There is no relevant use of pomalidomide in children aged 0-17 years for the indication of multiple myeloma.</p><p>Method of administration</p><p>Oral use.</p><p>Imnovid hard capsules should be taken orally at the same time each day. The capsules should not be opened, broken or chewed (see section 6.6). The capsules should be swallowed whole, preferably with water, with or without food. If the patient forgets to take a dose of pomalidomide on one day, then the patient should take the normal prescribed dose as scheduled on the next day. Patients should not adjust the dose to make up for a missing dose on previous days.</p><p>It is recommended to press only on one end of the capsule to remove it from the blister thereby reducing the risk of capsule deformation or breakage.</p><p>For information on other medicinal products given in combination with Imnovid, refer to the respective current SmPC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Pregnancy.
-	Women of childbearing potential, unless all the conditions of the i-SECURE (Pregnancy •	Prevention Programme) are met (see sections 4.4 and 4.6).
-	Male patients unable to follow or comply with the required contraceptive measures (see section
•	4.4).
•	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
For information on other medicinal products given in combination with Imnovid, refer to the respective current SmPC.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Teratogenicity</p><p>Pomalidomide must not be taken during pregnancy, since a teratogenic effect is expected. Pomalidomide is structurally related to thalidomide. Thalidomide is a known human teratogen that causes severe life-threatening birth defects. Pomalidomide was found to be teratogenic in both rats and rabbits when administered during the period of major organogenesis (see section 5.3).</p><p>The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.</p><p>Criteria for women of non-childbearing potential</p><p>A female patient or a female partner of a male patient is considered of non-childbearing potential if she meets at least one of the following criteria:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Age &ge; 50 years and naturally amenorrhoeic for &ge; 1 year (amenorrhoea following cancer therapy or during breast-feeding does not rule out childbearing potential)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Premature ovarian failure confirmed by a specialist gynaecologist &nbsp;&nbsp; Previous bilateral salpingo-oophorectomy, or hysterectomy &nbsp;&nbsp; XY genotype, Turner syndrome, uterine agenesis.</p><p>Counselling</p><p>For women of childbearing potential, pomalidomide is contraindicated unless all of the following are met:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the expected teratogenic risk to the unborn child</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the need for effective contraception, without interruption, at least 4 weeks before starting treatment, throughout the entire duration of treatment, and at least 4 weeks after the end of treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Even if a woman of childbearing potential has amenorrhoea she must follow all the advice on effective contraception</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She should be capable of complying with effective contraceptive measures</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She is informed and understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the need to commence the treatment as soon as pomalidomide is dispensed following a negative pregnancy test</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the need and accepts to undergo pregnancy testing at least every 4 weeks except in case of confirmed tubal sterilisation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She acknowledges that she understands the hazards and necessary precautions associated with the use of pomalidomide.</p><p>The prescriber must ensure that for women of childbearing potential:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patient complies with the conditions of the Pregnancy Prevention Programme, including confirmation that she has an adequate level of understanding</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patient has acknowledged the aforementioned conditions.</p><p>For male patients taking pomalidomide, pharmacokinetic data has demonstrated that pomalidomide is present in human semen during treatment. As a precaution, and taking into account special populations with potentially prolonged elimination time such as hepatic impairment, all male patients taking pomalidomide must meet the following conditions:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; He understands the expected teratogenic risk if engaged in sexual activity with a pregnant woman or a woman of childbearing potential</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; He understands the need for the use of a condom if engaged in sexual activity with a pregnant woman or a woman of childbearing potential not using effective contraception, throughout treatment duration, during dose interruption and for 7 days after dose interruptions and/or cessation of treatment. This includes vasectomised males who should wear a condom if engaged in sexual activity with a pregnant woman or a woman of childbearing potential as seminal fluid may still contain pomalidomide in the absence of spermatozoa.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; He understands that if his female partner becomes pregnant whilst he is taking pomalidomide or 7 days after he has stopped taking pomalidomide, he should inform his treating physician immediately and that it is recommended to refer the female partner to a physician specialised or experienced in teratology for evaluation and advice.</p><p>Contraception</p><p>Women of childbearing potential must use at least one effective method of contraception for at least 4 weeks before therapy, during therapy, and until at least 4 weeks after pomalidomide therapy and even in case of dose interruption unless the patient commits to absolute and continuous abstinence confirmed on a monthly basis. If not established on effective contraception, the patient must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.</p><p>The following can be considered to be examples of suitable methods of contraception:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Implant</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Levonorgestrel-releasing intrauterine system</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medroxyprogesterone acetate depot</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tubal sterilisation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ovulation inhibitory progesterone-only pills (i.e. desogestrel)</p><p>Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking pomalidomide and dexamethasone, combined oral contraceptive pills are not recommended (see also section 4.5). If a patient is currently using combined oral contraception the patient should switch to one of the effective methods listed above. The risk of venous thromboembolism continues for 4-6 weeks after discontinuing combined oral contraception. The efficacy of contraceptive steroids may be reduced during cotreatment with dexamethasone (see section 4.5).</p><p>Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics should be considered particularly in patients with neutropenia.</p><p>Insertion of copper-releasing intrauterine devices is not recommended due to the potential risks of infection at the time of insertion and menstrual blood loss which may compromise patients with severe neutropenia or severe thrombocytopenia.</p><p>Pregnancy testing</p><p>According to local practice, medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/mL must be performed for women of childbearing potential as outlined below. This requirement includes women of childbearing potential who practice absolute and continuous abstinence. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of pomalidomide to women of childbearing potential should occur within 7 days of the prescription.</p><p>Prior to starting treatment</p><p>A medically supervised pregnancy test should be performed during the consultation, when pomalidomide is prescribed, or in the 3 days prior to the visit to the prescriber once the patient had been using effective contraception for at least 4 weeks. The test should ensure the patient is not pregnant when she starts treatment with pomalidomide.</p><p>Follow-up and end of treatment</p><p>A medically supervised pregnancy test should be repeated at least every 4 weeks, including at least 4 weeks after the end of treatment, except in the case of confirmed tubal sterilisation. These pregnancy tests should be performed on the day of the prescribing visit or in the 3 days prior to the visit to the prescriber.</p><p>Additional precautions</p><p>Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment.</p><p>Patients should not donate blood, semen or sperm during treatment (including during dose interruptions) and for 7 days following discontinuation of pomalidomide.</p><p>Educational materials, prescribing and dispensing restrictions</p><p>In order to assist patients in avoiding foetal exposure to pomalidomide, the Marketing Authorisation Holder will provide educational material to health care professionals to reinforce the warnings about the expected teratogenicity of pomalidomide, to provide advice on contraception before therapy is started, and to provide guidance on the need for pregnancy testing. The prescriber must inform the patient about the expected teratogenic risk and the strict pregnancy prevention measures as specified in the Pregnancy Prevention Programme and provide patients with appropriate patient educational brochure, patient card and/or equivalent tool in accordance with the national implemented patient card system. A national controlled distribution system has been implemented in collaboration with each National Competent Authority. The controlled distribution system includes the use of a patient card and/or equivalent tool for prescribing and /or dispensing controls, and the collection of detailed data relating to the indication in order to monitor the off-label use within the national territory. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of pomalidomide to women of childbearing potential should occur within 7 days of the prescription and following a medically supervised negative pregnancy test result. Prescriptions for women of childbearing potential can be for a maximum duration of 4 weeks, and prescriptions for all other patients can be for a maximum duration of 12 weeks.</p><p>Haematological events</p><p>Neutropenia was the most frequently reported Grade 3 or 4 haematological adverse reaction in patients with relapsed/refractory multiple myeloma, followed by anaemia and thrombocytopenia. Patients should be monitored for haematological adverse reactions, especially neutropenia. Patients should be advised to report febrile episodes promptly. Physicians should observe patients for signs of bleeding including epistaxes, especially with use of concomitant medicinal products known to increase the risk of bleeding (see section 4.8). Complete blood counts should be monitored at baseline, weekly for the first 8 weeks and monthly thereafter. A dose modification may be required (see section 4.2). Patients may require use of blood product support and /or growth factors.</p><p>Thromboembolic events</p><p>Patients receiving pomalidomide either in combination with bortezomib and dexamethasone or in combination with dexamethasone have developed venous thromboembolic events (predominantly deep vein thrombosis and pulmonary embolism) and arterial thrombotic events (myocardial infarction and cerebrovascular accident). Patients with known risk factors for thromboembolism &ndash; including prior thrombosis &ndash; should be closely monitored. Action should be taken to try to minimise all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia). Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, arm or leg swelling. Anti-coagulation therapy (unless contraindicated) is recommended, (such as acetylsalicylic acid, warfarin, heparin or clopidogrel), especially in patients with additional thrombotic risk factors. A decision to take prophylactic measures should be made after a careful assessment of the individual patient&rsquo;s underlying risk factors. In clinical studies, patients received prophylactic acetylsalicylic acid or alternative anti-thrombotic therapy. The use of erythropoietic agents carries a risk of thrombotic events including thromboembolism. Therefore, erythropoietic agents, as well as other agents that may increase the risk of thromboembolic events, should be used with caution.</p><p>Peripheral neuropathy</p><p>Patients with ongoing &ge; Grade 2 peripheral neuropathy were excluded from clinical studies with pomalidomide. Appropriate caution should be exercised when considering the treatment of such patients with pomalidomide.</p><p>Significant cardiac dysfunction</p><p>Patients with significant cardiac dysfunction (congestive heart failure [NY Heart Association Class III or IV]; myocardial infarction within 12 months of starting study; unstable or poorly controlled angina pectoris) were excluded from clinical studies with pomalidomide. Cardiac events, including congestive cardiac failure, pulmonary oedema and atrial fibrillation (see section 4.8), have been reported, mainly in patients with pre-existing cardiac disease or cardiac risk factors. Appropriate caution should be exercised when considering the treatment of such patients with pomalidomide, including periodic monitoring for signs or symptoms of cardiac events.</p><p>Tumour lysis syndrome</p><p>Patients at greatest risk of tumour lysis syndrome are those with high tumour burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.</p><p>Second primary malignancies</p><p>Second primary malignancies, such as non-melanoma skin cancer, have been reported in patients receiving pomalidomide (see section 4.8). Physicians should carefully evaluate patients before and during treatment using standard cancer screening for occurrence of second primary malignancies and institute treatment as indicated.</p><p>Allergic reaction and severe skin reactions</p><p>Angioedema and severe dermatologic reactions including SJS, TEN and DRESS have been reported with the use of pomalidomide (see section 4.8). Patients should be advised of the signs and symptoms of these reactions by their prescribers and should be told to seek medical attention immediately if they develop these symptoms. Pomalidomide must be discontinued for exfoliative or bullous rash, or if SJS, TEN or DRESS is suspected, and should not be resumed following discontinuation for these reactions. Patients with a prior history of serious allergic reactions associated with thalidomide or lenalidomide were excluded from clinical studies. Such patients may be at higher risk of hypersensitivity reactions and should not receive pomalidomide. Pomalidomide interruption or discontinuation should be considered for Grade 2-3 skin rash. Pomalidomide must be discontinued permanently for angioedema.</p><p>Dizziness and confusion</p><p>Dizziness and confusional state have been reported with pomalidomide. Patients must avoid situations where dizziness or confusion may be a problem and not to take other medicinal products that may cause dizziness or confusion without first seeking medical advice.</p><p>Interstitial lung disease (ILD)</p><p>ILD and related events, including cases of pneumonitis, have been observed with pomalidomide. Careful assessment of patients with an acute onset or unexplained worsening of pulmonary symptoms should be performed to exclude ILD. Pomalidomide should be interrupted pending investigation of these symptoms and if ILD is confirmed, appropriate treatment should be initiated. Pomalidomide should only be resumed after a thorough evaluation of the benefits and the risks.</p><p>Hepatic disorders</p><p>Markedly elevated levels of alanine aminotransferase and bilirubin have been observed in patients treated with pomalidomide (see section 4.8). There have also been cases of hepatitis that resulted in discontinuation of pomalidomide. Regular monitoring of liver function is recommended for the first 6 months of treatment with pomalidomide and as clinically indicated thereafter.</p><p>Infections</p><p>Reactivation of hepatitis B has been reported rarely in patients receiving pomalidomide in combination with dexamethasone who have previously been infected with the hepatitis B virus (HBV). Some of these cases have progressed to acute hepatic failure, resulting in discontinuation of pomalidomide. Hepatitis B virus status should be established before initiating treatment with pomalidomide. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended. Caution should be exercised when pomalidomide in combination with dexamethasone is used in patients previously infected with HBV, including patients who are anti-HBc positive but HBsAg negative. These patients should be closely monitored for signs and symptoms of active HBV infection throughout therapy.</p><p>Sodium content</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per capsule, i.e. essentially &lsquo;sodium-free&rsquo;.</p><p>For information on other medicinal products given in combination with Imnovid, refer to the respective current SmPC.</p><p>Progressive multifocal leukoencephalopathy (PML)<br />Cases of progressive multifocal<br />leukoencephalopathy, including fatal cases, have<br />been reported with pomalidomide. PML was<br />reported several months to several years after<br />starting the treatment with pomalidomide. Cases<br />have generally been reported in patients taking<br />concomitant dexamethasone or prior treatment<br />with other immunosuppressive chemotherapy.<br />Physicians should monitor patients at regular</p><p>intervals and should consider PML in the<br />differential diagnosis in patients with new or<br />worsening neurological symptoms, cognitive or<br />behavioural signs or symptoms. Patients should<br />also be advised to inform their partner or<br />caregivers about their treatment, since they may<br />notice symptoms that the patient is not aware of.<br />The evaluation for PML should be based on<br />neurological examination, magnetic resonance<br />imaging of the brain, and cerebrospinal fluid<br />analysis for JC virus (JCV) DNA by polymerase<br />chain reaction (PCR) or a brain biopsy with<br />testing for JCV. A negative JCV PCR does not<br />exclude PML. Additional follow-up and<br />evaluation may be warranted if no alternative<br />diagnosis can be established.<br />If PML is suspected, further dosing must be<br />suspended until PML has been excluded. If PML<br />is confirmed, pomalidomide must be<br />permanently discontinued.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of pomalidomide on other medicinal products</p><p>Pomalidomide is not anticipated to cause clinically relevant pharmacokinetic drug-drug interactions due to P450 isoenzyme inhibition or induction or transporter inhibition when co-administered with substrates of these enzymes or transporters. The potential for such drug-drug interactions, including the potential impact of pomalidomide on the pharmacokinetics of combined oral contraceptives, has not been evaluated clinically (see section 4.4 Teratogenicity).</p><p>Effect of other medicinal products on pomalidomide</p><p>Pomalidomide is partly metabolised by CYP1A2 and CYP3A4/5. It is also a substrate for P-glycoprotein. Co-administration of pomalidomide with the strong CYP3A4/5 and P-gp inhibitor ketoconazole, or the strong CYP3A4/5 inducer carbamazepine, had no clinically relevant effect on exposure to pomalidomide. Co-administration of the strong CYP1A2 inhibitor fluvoxamine with pomalidomide in the presence of ketoconazole, increased mean exposure to pomalidomide by 107% with a 90% confidence interval [91% to</p><p>124%] compared to pomalidomide plus ketoconazole. In a second study to evaluate the contribution of a</p><p>CYP1A2 inhibitor alone to metabolism changes, co-administration of fluvoxamine alone with pomalidomide increased mean exposure to pomalidomide by 125% with a 90% confidence interval [98% to 157%] compared to pomalidomide alone. If strong inhibitors of CYP1A2 (e.g. ciprofloxacin, enoxacin and fluvoxamine) are co-administered with pomalidomide, reduce the dose of pomalidomide by 50%.</p><p>Dexamethasone</p><p>Co-administration of multiple doses of up to 4 mg pomalidomide with 20 mg to 40 mg dexamethasone (a weak to moderate inducer of several CYP enzymes including CYP3A) to patients with multiple myeloma had no effect on the pharmacokinetics of pomalidomide compared with pomalidomide administered alone.</p><p>The effect of dexamethasone on warfarin is unknown. Close monitoring of warfarin concentration is advised during treatment.</p><p>For information on other medicinal products given in combination with Imnovid, refer to the respective current SmPC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential / Contraception in males and females</p><p>Women of childbearing potential should use effective method of contraception. If pregnancy occurs in a woman treated with pomalidomide, treatment must be stopped and the patient should be referred to a physician specialised or experienced in teratology for evaluation and advice. If pregnancy occurs in a partner of a male patient taking pomalidomide, it is recommended to refer the female partner to a physician specialised or experienced in teratology for evaluation and advice. Pomalidomide is present in human semen. As a precaution, all male patients taking pomalidomide should use condoms throughout treatment duration, during dose interruption and for 7 days after cessation of treatment if their partner is pregnant or of childbearing potential and has no contraception (see sections 4.3 and 4.4).</p><p>Pregnancy</p><p>A teratogenic effect of pomalidomide in humans is expected. Pomalidomide is contraindicated during pregnancy and in women of childbearing potential, except when all the conditions for pregnancy prevention have been met, see section 4.3 and section 4.4.</p><p>Breast-feeding</p><p>It is unknown whether pomalidomide is excreted in human milk. Pomalidomide was detected in milk of lactating rats following administration to the mother. Because of the potential for adverse reactions in breastfed infants from pomalidomide, a decision must be made whether to discontinue breast-feeding or to discontinue the medicinal product, taking into account the benefit of breast-feeding for the child and the benefit of the therapy for the woman.</p><p>Fertility</p><p>Pomalidomide was found to impact negatively on fertility and be teratogenic in animals. Pomalidomide crossed the placenta and was detected in foetal blood following administration to pregnant rabbits, see section 5.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pomalidomide has minor or moderate influence on the ability to drive and use machines. Fatigue, depressed level of consciousness, confusion, and dizziness have been reported with the use of pomalidomide. If affected, patients should be instructed not to drive cars, use machines or perform hazardous tasks while being treated with pomalidomide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p> Pomalidomide in combination with bortezomib and dexamethasone</p><p>The most commonly reported blood and lymphatic system disorders were neutropenia (46.8%), thrombocytopenia (36.7%) and anaemia (28.4%). The most frequently reported adverse reaction was peripheral sensory neuropathy (47.8%). The most commonly reported Grade 3 or 4 adverse reactions were blood and lymphatic system disorders including neutropenia (41.7%), thrombocytopenia (27.3%) and anaemia (14.0%). The most commonly reported serious adverse reaction was pneumonia (11.5%). Other serious adverse reactions reported included pyrexia (4.0%), lower respiratory tract infection (2.9%), pulmonary embolism (2.9%), influenza (2.9%), and acute kidney injury (2.9%).</p><p> Pomalidomide in combination with dexamethasone</p><p>The most commonly reported adverse reactions in clinical studies have been blood and lymphatic system disorders including anaemia (45.7%), neutropenia (45.3%) and thrombocytopenia (27%); in general disorders and administration site conditions including fatigue (28.3%), pyrexia (21%) and oedema peripheral (13%); and in infections and infestations including pneumonia (10.7%). Peripheral neuropathy adverse reactions were reported in 12.3% of patients and venous embolic or thrombotic (VTE) adverse reactions were reported in 3.3% of patients. The most commonly reported Grade 3 or 4 adverse reactions were in the blood and lymphatic system disorders including neutropenia (41.7%), anaemia (27%) and thrombocytopenia (20.7%); in infections and infestations including pneumonia (9%); and in general disorders and administration site conditions including fatigue (4.7%), pyrexia (3%) and oedema peripheral (1.3%). The most commonly reported serious adverse reaction was pneumonia (9.3%). Other serious adverse reactions reported included febrile neutropenia (4.0%), neutropenia (2.0%), thrombocytopenia (1.7%) and VTE adverse reactions (1.7%).</p><p>Adverse reactions tended to occur more frequently within the first 2 cycles of treatment with pomalidomide.</p><p>Tabulated list of adverse reactions</p><p> Pomalidomide in combination with bortezomib and dexamethasone</p><p>In randomised study CC-4047-MM-007, 278 patients received pomalidomide, bortezomib and dexamethasone (Pom+Btz+Dex arm). See section 4.2 for dosing information.</p><p>The adverse reactions observed in patients treated with pomalidomide in combination with bortezomib and dexamethasone are listed in Table 7 by system organ class (SOC) and frequency for all adverse reactions and for Grade 3 or 4 adverse reactions.</p><p>Frequencies for Pom+Btz+Dex (any grade) are defined in accordance with current guidance, as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10); and uncommon (&ge;1/1,000 to &lt;1/100).</p><p><strong>Table 7. All Adverse Reactions (ADRs) reported in clinical trial MM-007 in patients treated with pomalidomide in combination with bortezomib and dexamethasone.</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class/ </strong></p><p><strong>Preferred Term</strong></p></td><td><p><strong>All Adverse Reactions </strong></p><p><strong>/Frequency </strong></p></td><td><p><strong>Grade 3&minus;4 Adverse Reactions </strong></p><p><strong>/Frequency </strong></p></td></tr><tr><td><p><strong>Infections and infestations</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Pneumonia</p><p>Bronchitis</p><p>Upper respiratory tract infection</p><p>Viral upper respiratory tract infection</p><p><strong><u>Common</u></strong></p><p>Sepsis</p><p>Septic shock</p><p><em>Clostridium difficile </em>colitis</p><p>Respiratory tract infection</p><p>Lower respiratory tract infection</p><p>Lung infection</p><p>Influenza</p><p>Bronchiolitis</p><p>Urinary tract infection</p></td><td><p><strong><u>Very Common </u></strong>Pneumonia</p><p><strong><u>Common</u></strong></p><p>Sepsis</p><p>Septic shock</p><p><em>Clostridium difficile </em>colitis</p><p>Bronchitis</p><p>Upper respiratory tract infection</p><p>Respiratory tract infection</p><p>Lower respiratory tract infection</p><p>Lung infection</p><p>Influenza</p><p>Bronchiolitis</p><p>Urinary tract infection</p></td></tr><tr><td><p><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Basal cell carcinoma</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class/ </strong></p><p><strong>Preferred Term</strong></p></td><td><p><strong>All Adverse Reactions </strong></p><p><strong>/Frequency </strong></p></td><td><p><strong>Grade 3&minus;4 Adverse Reactions </strong></p><p><strong>/Frequency </strong></p></td></tr><tr><td><p><strong>Blood and lymphatic system disorders</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Neutropenia</p><p>Thrombocytopenia</p><p>Leucopenia Anaemia</p><p><strong><u>Common</u></strong></p><p>Febrile neutropenia</p><p>Lymphopenia</p></td><td><p><strong><u>Very Common</u></strong></p><p>Neutropenia</p><p>Thrombocytopenia</p><p>Anaemia</p><p><strong><u>Common</u></strong></p><p>Febrile neutropenia</p><p>Leucopenia</p><p>Lymphopenia</p></td></tr><tr><td><p><strong>Metabolism and nutrition disorders</strong></p></td><td><p><strong><u>Very Common </u></strong>Hypokalaemia</p><p>Hyperglycaemia</p><p><strong><u>Common</u></strong></p><p>Hypomagnesaemia</p><p>Hypocalcaemia</p><p>Hypophosphataemia</p><p>Hyperkalaemia</p><p>Hypercalcaemia</p></td><td><p><strong><u>Common</u></strong></p><p>Hypokalaemia</p><p>Hyperglycaemia</p><p>Hypomagnaesaemia</p><p>Hypocalcaemia</p><p>Hypophosphataemia</p><p>Hyperkalaemia</p><p>Hypercalcaemia</p></td></tr><tr><td><p><strong>Psychiatric disorders</strong></p></td><td><p><strong><u>Very Common </u></strong>Insomnia</p><p><strong><u>Common</u></strong></p><p>Depression</p></td><td><p><strong><u>Common</u></strong></p><p>Depression</p><p>Insomnia</p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Peripheral sensory neuropathy</p><p>Dizziness Tremor</p><p><strong><u>Common</u></strong></p><p>Syncope</p><p>Peripheral sensorimotor neuropathy</p><p>Paraesthesia</p><p>Dysgeusia</p></td><td><p><strong><u>Common</u></strong></p><p>Syncope</p><p>Peripheral sensory neuropathy</p><p>Peripheral sensorimotor neuropathy</p><p><strong><u>Uncommon</u></strong></p><p>Dizziness Tremor</p></td></tr><tr><td><p><strong>Eye disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Cataract</p></td><td><p><strong><u>Common</u></strong></p><p>Cataract</p></td></tr><tr><td><p><strong>Cardiac disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Atrial fibrillation</p></td><td><p><strong><u>Common</u></strong></p><p>Atrial fibrillation</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class/ </strong></p><p><strong>Preferred Term</strong></p></td><td><p><strong>All Adverse Reactions </strong></p><p><strong>/Frequency </strong></p></td><td><p><strong>Grade 3&minus;4 Adverse Reactions </strong></p><p><strong>/Frequency </strong></p></td></tr><tr><td><p><strong>Vascular disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Deep vein thrombosis</p><p>Hypotension</p><p>Hypertension</p></td><td><p><strong><u>Common</u></strong></p><p>Hypotension</p><p>Hypertension</p><p><strong><u>Uncommon</u></strong></p><p>Deep vein thrombosis</p></td></tr><tr><td><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Dyspnoea</p><p>Cough</p><p><strong><u>Common</u></strong></p><p>Pulmonary embolism</p></td><td><p><strong><u>Common</u></strong></p><p>Pulmonary embolism</p><p>Dyspnoea</p></td></tr><tr><td><p><strong>Gastrointestinal disorders</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Diarrhoea</p><p>Vomiting</p><p>Nausea</p><p>Constipation</p><p><strong><u>Common</u></strong></p><p>Abdominal pain</p><p>Abdominal pain upper</p><p>Stomatitis</p><p>Dry mouth</p><p>Abdominal distension</p></td><td><p><strong><u>Common</u></strong></p><p>Diarrhoea</p><p>Vomiting</p><p>Abdominal pain Constipation</p><p><strong><u>Uncommon</u></strong></p><p>Abdominal pain upper</p><p>Stomatitis</p><p>Nausea</p><p>Abdominal distension</p></td></tr><tr><td><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Rash</p></td><td><p><strong><u>Common</u></strong></p><p>Rash</p></td></tr><tr><td><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Muscular weakness</p><p>Back pain</p><p><strong><u>Common</u></strong></p><p>Bone pain</p><p>Muscle spasms</p></td><td><p><strong><u>Common</u></strong></p><p>Muscular weakness</p><p>Back pain</p><p><strong><u>Uncommon</u></strong></p><p>Bone pain</p></td></tr><tr><td><p><strong>Renal and urinary disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Acute kidney injury</p><p>Chronic kidney injury</p><p>Urinary retention</p></td><td><p><strong><u>Common</u></strong></p><p>Acute kidney injury</p><p>Chronic kidney injury</p><p>Urinary retention</p></td></tr><tr><td><p><strong>System Organ Class/ </strong></p><p><strong>Preferred Term</strong></p></td><td><p><strong>All Adverse Reactions </strong></p><p><strong>/Frequency </strong></p></td><td><p><strong>Grade 3&minus;4 Adverse Reactions </strong></p><p><strong>/Frequency </strong></p></td></tr><tr><td><p><strong>General disorders and administration site conditions</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Fatigue</p><p>Pyrexia</p><p>Oedema peripheral</p><p><strong><u>Common</u></strong></p><p>Non-cardiac chest pain</p><p>Oedema</p></td><td><p><strong><u>Common</u></strong></p><p>Fatigue</p><p>Pyrexia</p><p>Non-cardiac chest pain</p><p>Oedema peripheral</p><p>Oedema</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Alanine aminotransferase increased</p><p>Weight decreased</p></td><td><p><strong><u>Common</u></strong></p><p>Weight decreased</p><p><strong><u>Uncommon</u></strong></p><p>Alanine aminotransferase increased</p></td></tr><tr><td><p><strong>Injury, poisoning and procedural complications</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Fall</p></td><td><p><strong><u>Uncommon</u></strong></p><p>Fall</p></td></tr></tbody></table><p>Tabulated list of adverse reactions</p><p> Pomalidomide in combination with dexamethasone</p><p>In randomised study CC-4047-MM-003, 302 patients with relapsed and refractory multiple myeloma were exposed to 4 mg pomalidomide administered once daily for 21 days of each 28&ndash;day cycle in combination with a weekly low dose of dexamethasone.</p><p>The adverse reactions observed in patients treated with pomalidomide plus dexamethasone are listed below in Table 8 by system organ class (SOC) and frequency for all adverse reactions (ADRs) and for Grade 3 or 4 adverse reactions.</p><p>The frequencies of adverse reactions are those reported in the pomalidomide plus dexamethasone arm of study CC-4047-MM-003 (n = 302). Within each SOC and frequency grouping, adverse reactions are presented in order of decreasing seriousness. Frequencies are defined in accordance with current guidance, as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10); and uncommon (&ge; 1/1,000 to &lt; 1/100).</p><p><strong>Table 8. ADRs reported in clinical study MM-003 in patients treated with pomalidomide in combination with dexamethasone.</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class/ Preferred Term</strong></p></td><td><p><strong>All ADRs/Frequency</strong></p></td><td><p><strong>Grade 3&minus;4 ADRs/Frequency</strong></p></td></tr><tr><td><p><strong>Infections and infestations</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Pneumonia (bacterial, viral and fungal infections, including opportunistic infections)</p><p><strong><u>Common</u></strong></p><p>Neutropenic sepsis</p><p>Bronchopneumonia</p><p>Bronchitis</p><p>Respiratory tract infection</p><p>Upper respiratory tract infection</p><p>Nasopharyngitis</p><p>Herpes zoster</p></td><td><p><strong><u>Common</u></strong></p><p>Neutropenic sepsis</p><p>Pneumonia (bacterial, viral and fungal infections, including</p><p>opportunistic infections)</p><p>Bronchopneumonia</p><p>Respiratory tract infection</p><p>Upper respiratory tract infection</p><p><strong><u>Uncommon</u></strong></p><p>Bronchitis</p><p>Herpes zoster</p></td></tr><tr><td><p><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong></p></td><td><p><strong><u>Uncommon</u></strong></p><p>Basal cell carcinoma of the skin,</p><p>Squamous cell carcinoma of the skin</p></td><td><p><strong><u>Uncommon</u></strong></p><p>Basal cell carcinoma of the skin,</p><p>Squamous cell carcinoma of the skin</p></td></tr><tr><td><p><strong>Blood and lymphatic system disorders</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Neutropenia</p><p>Thrombocytopenia</p><p>Leucopenia Anaemia</p><p><strong><u>Common</u></strong></p><p>Febrile neutropenia</p></td><td><p><strong><u>Very Common</u></strong></p><p>Neutropenia</p><p>Thrombocytopenia Anaemia</p><p><strong><u>Common</u></strong></p><p>Febrile neutropenia</p><p>Leucopenia</p></td></tr><tr><td><p><strong>Metabolism and nutrition disorders</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Decreased appetite</p><p><strong><u>Common</u></strong></p><p>Hyperkalaemia</p><p>Hyponatraemia</p></td><td><p><strong><u>Common</u></strong></p><p>Hyperkalaemia</p><p>Hyponatraemia</p><p><strong><u>Uncommon</u></strong></p><p>Decreased appetite</p></td></tr><tr><td><p><strong>Psychiatric disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Confusional state</p></td><td><p><strong><u>Common</u></strong></p><p>Confusional state</p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Depressed level of consciousness</p><p>Peripheral sensory neuropathy</p><p>Dizziness Tremor</p></td><td><p><strong><u>Common</u></strong></p><p>Depressed level of consciousness</p><p><strong><u>Uncommon</u></strong></p><p>Peripheral sensory neuropathy</p><p>Dizziness</p><p>Tremor</p></td></tr><tr><td><p><strong>System Organ Class/ </strong></p><p><strong>Preferred Term</strong></p></td><td><p><strong>All ADRs/Frequency</strong></p></td><td><p><strong>Grade 3&minus;4 ADRs/Frequency</strong></p></td></tr><tr><td><p><strong>Ear and labyrinth disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Vertigo</p></td><td><p><strong><u>Common</u></strong></p><p>Vertigo</p></td></tr><tr><td><p><strong>Vascular disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Deep vein thrombosis</p></td><td><p><strong><u>Uncommon</u></strong></p><p>Deep vein thrombosis</p></td></tr><tr><td><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Dyspnoea Cough</p><p><strong><u>Common</u></strong></p><p>Pulmonary embolism</p></td><td><p><strong><u>Common</u></strong></p><p>Dyspnoea</p><p><strong><u>Uncommon</u></strong></p><p>Pulmonary embolism</p><p>Cough</p></td></tr><tr><td><p><strong>Gastrointestinal disorders</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Diarrhoea</p><p>Nausea</p><p>Constipation</p><p><strong><u>Common</u></strong></p><p>Vomiting</p><p>Gastrointestinal haemorrhage</p></td><td><p><strong><u>Common</u></strong></p><p>Diarrhoea</p><p>Vomiting</p><p>Constipation</p><p><strong><u>Uncommon</u></strong></p><p>Nausea</p><p>Gastrointestinal haemorrhage</p></td></tr><tr><td><p><strong>Hepatobiliary disorders</strong></p></td><td><p><strong><u>Uncommon</u></strong></p><p>Hyperbilirubinaemia</p></td><td><p><strong><u>Uncommon</u></strong></p><p>Hyperbilirubinaemia</p></td></tr><tr><td><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Rash</p><p>Pruritus</p></td><td><p><strong><u>Common</u></strong></p><p>Rash</p></td></tr><tr><td><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Bone pain</p><p>Muscle spasms</p></td><td><p><strong><u>Common</u></strong></p><p>Bone pain</p><p><strong><u>Uncommon</u></strong></p><p>Muscle spasms</p></td></tr><tr><td><p><strong>Renal and urinary disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Renal failure</p><p>Urinary retention</p></td><td><p><strong><u>Common</u></strong></p><p>Renal failure</p><p><strong><u>Uncommon</u></strong></p><p>Urinary retention</p></td></tr><tr><td><p><strong>Reproductive system and breast disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Pelvic pain</p></td><td><p><strong><u>Common</u></strong></p><p>Pelvic pain</p></td></tr><tr><td><p><strong>General disorders and administration site conditions</strong></p></td><td><p><strong><u>Very Common</u></strong></p><p>Fatigue</p><p>Pyrexia</p><p>Oedema peripheral</p></td><td><p><strong><u>Common</u></strong></p><p>Fatigue</p><p>Pyrexia</p><p>Oedema peripheral</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Neutrophil count decreased</p><p>White blood cell count decreased</p><p>Platelet count decreased</p><p>Alanine aminotransferase increased</p></td><td><p><strong><u>Common</u></strong></p><p>Neutrophil count decreased</p><p>White blood cell count decreased</p><p>Platelet count decreased</p><p>Alanine aminotransferase increased</p></td></tr></tbody></table><p><u>Tabulated list of post-marketing adverse reactions </u>In addition to the above adverse reactions identified from the pivotal clinical trials, the following Table 9 is derived from data gathered from post-marketing surveillance.</p><p>Frequencies are defined in accordance with current<br />guidance, as: very common (&ge; 1/10), common (&ge;<br />1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100)<br />and not known (frequency cannot be determined).<br />Paediatric population<br />Adverse reactions reported in paediatric patients<br />(aged 4 to 18 years) with recurrent or progressive<br />brain tumours were consistent with the known<br />pomalidomide safety profile in adult patients (see<br />section 5.1).</p><p><strong>Table 9. ADRs reported in post-marketing use in patients treated with pomalidomide.</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class/ </strong></p><p><strong>Preferred Term</strong></p></td><td><p><strong>All Adverse Reactions </strong></p><p><strong>/Frequency </strong></p></td><td><p><strong>Grade 3&minus;4 Adverse Reactions </strong></p><p><strong>/Frequency </strong></p></td></tr><tr><td><p><strong>Infections and infestations</strong></p></td><td><p><strong><u>Not Known</u></strong></p><p>Hepatitis B reactivation</p></td><td><p><strong><u>Not Known</u></strong></p><p>Hepatitis B reactivation</p></td></tr><tr><td><p><strong>Blood and lymphatic system disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Pancytopenia</p></td><td><p><strong><u>Common</u></strong></p><p>Pancytopenia</p></td></tr><tr><td><p><strong>Metabolism and nutrition disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Hyperuricaemia</p><p><strong><u>Uncommon</u></strong></p><p>Tumour lysis syndrome</p></td><td><p><strong><u>Common</u></strong></p><p>Hyperuricaemia</p><p><strong><u>Uncommon</u></strong></p><p>Tumour lysis syndrome</p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Intracranial haemorrhage</p><p><strong><u>Uncommon</u></strong></p><p>Cerebrovascular accident</p></td><td><p><strong><u>Uncommon</u></strong></p><p>Cerebrovascular accident</p><p>Intracranial haemorrhage</p></td></tr><tr><td><p><strong>Cardiac disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Cardiac failure</p><p>Atrial fibrillation</p><p>Myocardial infarction</p></td><td><p><strong><u>Common</u></strong></p><p>Cardiac failure</p><p>Atrial fibrillation</p><p><strong><u>Uncommon</u></strong></p><p>Myocardial infarction</p></td></tr><tr><td><p><strong>Immune system disorders </strong></p></td><td><p><strong><u>Common</u></strong></p><p>Angioedema</p><p>Urticaria</p></td><td><p><strong><u>Uncommon</u></strong></p><p>Angioedema</p><p>Urticaria</p></td></tr><tr><td><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Epistaxis</p><p>Interstitial lung disease</p></td><td><p><strong><u>Uncommon</u></strong></p><p>Epistaxis</p><p>Interstitial lung disease</p></td></tr><tr><td><p><strong>Hepatobiliary disorders</strong></p></td><td><p><strong><u>Uncommon</u></strong></p><p>Hepatitis</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td><p><strong><u>Not Known</u></strong></p><p>Drug Reaction with Eosinophilia and</p><p>Systemic Symptoms</p><p>Toxic Epidermal Necrolysis</p><p>Stevens-Johnson Syndrome</p></td><td><p><strong><u>Not Known</u></strong></p><p>Drug Reaction with Eosinophilia and</p><p>Systemic Symptoms</p><p>Toxic Epidermal Necrolysis</p><p>Stevens-Johnson Syndrome</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td><p><strong><u>Common</u></strong></p><p>Blood uric acid increased</p></td><td><p><strong><u>Uncommon</u></strong></p><p>Blood uric acid increased</p></td></tr></tbody></table><p>Description of selected adverse reactions</p><p>Teratogenicity</p><p>Pomalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects. Pomalidomide was found to be teratogenic in both rats and rabbits when administered during the period of major organogenesis (see sections 4.6 and 5.3). If pomalidomide is taken during pregnancy, a teratogenic effect of pomalidomide in humans is expected (see section 4.4).</p><p>Neutropenia and thrombocytopenia</p><p>In patients receiving combination therapy with pomalidomide in clinical studies, neutropenia occurred in up to 46.8% of patients (41.7% Grade 3 or 4). Neutropenia did not lead to pomalidomide discontinuation in any patient and was infrequently serious.</p><p>Febrile neutropenia (FN) was reported in 3.2-6.7% of patients and was serious in 1.8-4.0% of patients (see section 4.2 and 4.4).</p><p>In patients receiving combination therapy with pomalidomide in clinical studies, thrombocytopenia occurred in 27.0-36.7% of patients. Thrombocytopenia was Grade 3 or 4 in 20.7-27.3% of patients, led to pomalidomide discontinuation in 0.7% of patients and was serious in 0.4-1.7% of patients (see sections 4.2 and 4.4).</p><p>Neutropenia and thrombocytopenia tended to occur more frequently within the first 2 cycles of treatment with pomalidomide.</p><p>Infection</p><p>Infection was the most common non haematological toxicity.</p><p>In patients receiving combination therapy with pomalidomide in clinical studies, infection occurred in 55.080.2% of patients (24.0-30.9% Grade 3 or 4). Upper respiratory tract infection and pneumonia were the most frequently occurring infections. Fatal infections (Grade 5) occurred in 2.7-4.0% of patients. Infections led to pomalidomide discontinuation in 2.0-2.9% of patients.</p><p>Thromboembolic events</p><p>Prophylaxis with acetylsalicylic acid (and other anticoagulants in high risk patients) was mandatory for all patients in clinical studies. Anticoagulation therapy (unless contraindicated) is recommended (see section 4.4).</p><p>In patients receiving combination therapy with pomalidomide in clinical studies, venous thromboembolic events (VTE) occurred in 3.3-11.5% of patients (1.3-5.4% Grade 3 or 4). VTE was reported as serious in 1.7-4.3% of patients, no fatal reactions were reported, and VTE was associated with pomalidomide discontinuation in up to 1.8% of patients.</p><p>Peripheral neuropathy  Pomalidomide in combination with bortezomib and dexamethasone</p><p>Patients with ongoing peripheral neuropathy &ge; Grade 2 with pain within 14 days prior to randomisation were excluded from clinical trials. Peripheral neuropathy occurred in 55.4 % of patients (10.8% Grade 3; 0.7% Grade 4). Exposure-adjusted rates were comparable across treatment arms. Approximately 30% of the patients experiencing peripheral neuropathy had a history of neuropathy at baseline. Peripheral neuropathy led to discontinuation of bortezomib in approximately 12.9% of patients, pomalidomide in 1.8% and dexamethasone in 2.2 - 8.9% of patients, respectively. Refer also to the bortezomib SmPC.</p><p> Pomalidomide in combination with dexamethasone</p><p>Patients with ongoing peripheral neuropathy &ge; Grade 2 were excluded from clinical studies. Peripheral neuropathy occurred in 12.3% of patients (1.0% Grade 3 or 4). No peripheral neuropathy reactions were</p><p>&nbsp;</p><p>reported as serious, and peripheral neuropathy led to dose discontinuation in 0.3% of patients (see section 4.4).</p><p>Haemorrhage</p><p>Haemorrhagic disorders have been reported with pomalidomide, especially in patients with risk factors such as concomitant medicinal products that increase susceptibility to bleeding. Haemorrhagic events have included epistaxis, intracranial haemorrhage and gastrointestinal haemorrhage.</p><p>Allergic reactions and severe skin reactions</p><p>Angioedema and severe cutaneous reactions including SJS, TEN and DRESS has been reported with the use of pomalidomide. Patients with a history of severe rash associated with lenalidomide or thalidomide should not receive pomalidomide (see section 4.4).</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p><strong>To report any side effect(s): </strong></p><p><strong>Saudi Arabia:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>- National Pharmacovigilance and Drug Safety Center (NPC)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222,</p><p>Exts: 2317-2356-2340</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: <u>npc.drug@sfda.gov.sa</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p><strong>United Arab Emirates:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Pharmacovigilance and Medical Device Section</p><p>P.O. Box: 1853 Dubai UAE Tel: 80011111</p><p>Email:&nbsp; <u>pv@mohap.gov.ae</u></p><p>&nbsp; Drug Department</p><p>&nbsp; Ministry of Health&nbsp;</p><p>&amp; Prevention</p><p>Dubai</p><p>23</p></td></tr></tbody></table><p><strong><em>Oman:</em></strong></p><p>Department of Pharmacovigilance &amp; Drug Information</p><p>Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>Ministry of Health, Sultanate of Oman</p><p>Phone Nos. 22357687 / 22357686</p><p>Fax: 22358489</p><p>Email: <u>dg-padc@moh.gov.om </u>Website : www.moh.gov.om</p><p>&middot; <strong><em>Other Countries:</em></strong></p><p><strong>- </strong>Please contact&nbsp;the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pomalidomide doses as high as 50 mg as a single dose in healthy volunteers, and 10 mg as once-daily multiple doses in multiple myeloma patients have been studied without reported serious adverse reactions related to overdose. In studies, pomalidomide was found to be removed by haemodialysis.</p><p>In the event of overdose, supportive care is advised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, Other immunosuppressantsATC code: L04AX06 <u>Mechanism of action</u></p><p>Pomalidomide has direct anti-myeloma tumoricidal activity, immunomodulatory activities and inhibits stromal cell support for multiple myeloma tumour cell growth. Specifically, pomalidomide inhibits proliferation and induces apoptosis of haematopoietic tumour cells. Additionally, pomalidomide inhibits the proliferation of lenalidomide-resistant multiple myeloma cell lines and synergises with dexamethasone in both lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumour cell apoptosis. Pomalidomide enhances T cell- and natural killer (NK) cell-mediated immunity and inhibits production of pro-inflammatory cytokines (e.g., TNF-&alpha; and IL-6) by monocytes. Pomalidomide also inhibits angiogenesis by blocking the migration and adhesion of endothelial cells.</p><p>Pomalidomide binds directly to the protein cereblon (CRBN), which is part of an E3 ligase complex that includes deoxyribonucleic acid (DNA) damage-binding protein 1(DDB1), cullin 4 (CUL4), and regulator of cullins-1 (Roc1), and can inhibit the auto-ubiquitination of CRBN within the complex. E3 ubiquitin ligases are responsible for the poly-ubiquitination of a variety of substrate proteins, and may partially explain the pleiotropic cellular effects observed with pomalidomide treatment.</p><p>In the presence of pomalidomide <em>in vitro</em>, substrate proteins Aiolos and Ikaros are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects. <em>In vivo</em>, pomalidomide therapy led to reduction in the levels of Ikaros in patients with relapsed lenalidomiderefractory multiple myeloma.</p><p>Clinical efficacy and safety</p><p> Pomalidomide in combination with bortezomib and dexamethasone</p><p>The efficacy and safety of pomalidomide in combination with bortezomib and low-dose dexamethasone</p><p>(Pom+Btz+LD-Dex) was compared with bortezomib and low-dose dexamethasone (Btz+LD-Dex) in a Phase III multi-centre, randomised, open-label study (CC-4047-MM-007), in previously treated adult patients with multiple myeloma, who had received at least one prior regimen, including lenalidomide and have demonstrated disease progression on or after the last therapy. A total of 559 patients were enrolled and randomised in the study: 281 in the Pom+Btz+LD-Dex arm and 278 in the Btz+LD-Dex arm. 54% of patients were male with median age for the overall population of 68 years (min, max: 27, 89 years). Approximately 70% of patients were refractory to lenalidomide (71.2% in Pom+Btz+LD-Dex, 68.7 % in Btz+LD-Dex). Approximately 40% of patients were in 1<sup>st </sup>relapse and approximately 73% of patients received bortezomib as prior treatment.</p><p>Patients in the Pom+Btz+LD-Dex arm were administered 4 mg pomalidomide orally on Days 1 to 14 of each 21-day cycle. Bortezomib (1.3 mg/m<sup>2</sup>/dose) was administered to patients in both study arms on Days 1, 4, 8 and 11 of a 21-day cycle for Cycles 1 to 8; and on Days 1 and 8 of a 21-day cycle for Cycles 9 and onwards. Low-dose dexamethasone (20 mg/day [&le; 75 years old] or 10 mg/day [&gt; 75 years old]) was administered to patients in both study arms on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle for Cycles 1 to 8; and on Days 1, 2, 8 and 9 of each subsequent 21-day cycle from Cycles 9 onwards. Doses were reduced and treatment was temporarily interrupted or stopped as needed to manage toxicity (see section 4.2).</p><p>The primary efficacy endpoint was Progression Free Survival (PFS) assessed by an Independent Response Adjudication Committee (IRAC) according to the IMWG criteria using the intent to treat population (ITT). After a median follow-up of 15.9 months, median PFS time was 11.20 months (95% CI: 9.66, 13.73) in the Pom+Btz+LD-Dex arm. In the Btz+LD-Dex arm, median PFS time was 7.1 months (95% CI: 5.88, 8.48).</p><p>Summary of overall efficacy data are presented in Table 10 using a cut-off date of 26 Oct 2017. KaplanMeier curve for PFS for the ITT population is provided in Figure 1.</p><p>Table 10. Summary of overall efficacy data</p><table border="0" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pom+Btz+LD-Dex (N = 281)</p></td><td style="vertical-align:top"><p>Btz+LD-Dex (N = 278)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS (months)</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>a </sup>time (95% CI) <sup>b</sup></p></td><td style="vertical-align:top"><p>11.20 (9.66, 13.73)</p></td><td style="vertical-align:top"><p>7.10 (5.88, 8.48)</p></td></tr><tr><td style="vertical-align:top"><p>HR <sup>c </sup>(95% CI), p-value<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.61 (0.49, 0.77), &lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>ORR, n (%)</strong></p></td><td style="vertical-align:top"><p>82.2 %</p></td><td style="vertical-align:top"><p>50.0%</p></td></tr><tr><td style="vertical-align:top"><p>sCR</p></td><td style="vertical-align:top"><p>9 (3.2)</p></td><td style="vertical-align:top"><p>2 (0.7)</p></td></tr><tr><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>35 (12.5)</p></td><td style="vertical-align:top"><p>9 (3.2)</p></td></tr><tr><td style="vertical-align:top"><p>VGPR</p></td><td style="vertical-align:top"><p>104 (37.0)</p></td><td style="vertical-align:top"><p>40 (14.4)</p></td></tr><tr><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>83 (29.5)</p></td><td style="vertical-align:top"><p>88 (31.7)</p></td></tr><tr><td style="vertical-align:top"><p>OR (95% CI) <sup>e</sup>, p-value<sup>f</sup></p></td><td colspan="2" style="vertical-align:top"><p>5.02 (3.35, 7.52), &lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>DoR (months)</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>a </sup>time (95% CI) <sup>b</sup></p></td><td style="vertical-align:top"><p>13.7 (10.94, 18.10)</p></td><td style="vertical-align:top"><p>10.94 (8.11, 14.78)</p></td></tr><tr><td style="vertical-align:top"><p>HR<sup>c </sup>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.76 (0.56, 1.02)</p></td></tr></tbody></table><p>Btz = bortezomib; CI = Confidence interval; CR = Complete response; DoR = Duration of response; HR = Hazard Ratio; LD-Dex = low-dose dexamethasone; OR = Odds ratio; ORR = Overall response rate; PFS = Progression free survival; POM = pomalidomide; PR = Partial Response; sCR = Stringent complete response VGPR = Very good partial response. <sup>a </sup>The median is based on the Kaplan-Meier estimate. <sup>b </sup>95% CI about the median. <sup>c </sup>Based on Cox proportional hazards model. <sup>d </sup>The p-value is based on a stratified log-rank test. <sup>e </sup>Odds ratio is for Pom+Btz+LD-Dex:Btz+LD-Dex.</p><p><sup>f </sup>The p-value is based on a CMH test, stratified by age (&lt;=75 vs &gt;75), Prior number of antimyeloma regimens (1 vs &gt;1), and Beta-2 microglobulin at screening (&lt; 3.5 mg/L versus &ge; 3.5 mg/L &mdash; &le; 5.5 mg/L versus &gt; 5.5 mg/L).</p><p>The median duration of treatment was 8.8 months (12 treatment cycles) in the Pom+Btz+LD-Dex arm and 4.9 months (7 treament cycles) in the Btz+LD-Dex arm.</p><p>The PFS advantage was more pronounced in patients who received only one prior line of therapy. In patients who received 1 prior antimyeloma line, median PFS time was 20.73 months (95% CI: 15.11, 27.99) in the Pom + Btz + LD-Dex arm and 11.63 months (95% CI: 7.52, 15.74) in the Btz + LD-Dex arm. A 46% risk reduction was observed with Pom + Btz + LD-Dex treatment (HR = 0.54, 95% CI: 0.36, 0.82).</p><p><strong>Figure 1. Progression Free Survival Based on IRAC Review of Response by IMWG Criteria (Stratified Log Rank Test) (ITT Population).</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_68577" o:spid="_x0000_s1059" style='width:443.75pt;height:248.4pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="56357,31546" o:gfxdata="UEsDBBQABgAIAAAAIQAfiHZoFgEAAFECAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSTW7DIBCF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==
">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Picture_x0020_7293" o:spid="_x0000_s1060" type="#_x0000_t75"
  style='position:absolute;width:56357;height:15788;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title=""/>
 </v:shape><v:shape id="Picture_x0020_7295" o:spid="_x0000_s1061" type="#_x0000_t75"
  style='position:absolute;top:15788;width:56357;height:15758;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg"
   o:title=""/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="592" height="331" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:443.75pt;height:248.4pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Data cutoff: 26 Oct 2017</p><p>As per an interim analysis for Overall Survival (OS), using a cut-off of 15 September 2018 (median follow-up period of 26.2 months), median OS time from Kaplan-Meier estimates was 40.5 months for the Pom + Btz + LD-Dex arm and 30.5 months for the Btz + LD-Dex arm; HR = 0.91, 95% CI: 0.70, 1.18, with an overall event rate of 43.3%.</p><p> <em>Pomalidomide in combination with dexamethasone</em></p><p>The efficacy and safety of pomalidomide in combination with dexamethasone were evaluated in a Phase III multi-centre, randomised, open-label study (CC-4047-MM-003), where pomalidomide plus low-dose dexamethasone therapy (Pom+LD-Dex) was compared to high-dose dexamethasone alone (HD-Dex) in previously treated adult patients with relapsed and refractory multiple myeloma, who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy. A total of 455 patients were enrolled in the study: 302 in the Pom+LD-Dex arm and 153 in the HD-Dex arm. The majority of patients were male (59%) and white (79%); the median age for the overall population was 64 years (min, max: 35, 87 years).</p><p>Patients in the Pom+LD-Dex arm were administered 4 mg pomalidomide orally on days 1 to 21 of each 28-day cycle. LD-Dex (40 mg) was administered once per day on days 1, 8, 15 and 22 of a 28-day cycle.</p><p>For the HD-Dex arm, dexamethasone (40 mg) was administered once per day on days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle. Patients &gt; 75 years of age started treatment with 20 mg dexamethasone. Treatment continued until patients had disease progression.</p><p>The primary efficacy endpoint was progression free survival (PFS) by International Myeloma Working</p><p>Group (IMWG criteria). For the intention to treat (ITT) population, median PFS time by Independent Review Adjudication Committee (IRAC) review based on IMWG criteria was 15.7 weeks (95% CI: 13.0,</p><p>20.1) in the Pom + LD-Dex arm; the estimated 26-week event-free survival rate was 35.99% (&plusmn;3.46%). In the HD-Dex arm, median PFS time was 8.0 weeks (95% CI: 7.0, 9.0); the estimated 26-week eventfree survival rate was 12.15% (&plusmn;3.63%).</p><p>Progression-free survival was evaluated in several relevant subgroups: gender, race, ECOG performance status, stratification factors (age, disease population, prior anti-myeloma therapies [2, &gt; 2]), selected parameters of prognostic significance (baseline beta-2 microglobulin level, baseline albumin levels, baseline renal impairment, and cytogenetic risk), and exposure and refractoriness to prior anti-myeloma therapies. Regardless of the subgroup evaluated, PFS was generally consistent with that observed in the ITT population for both treatment groups.</p><p>PFS is summarised in Table 11 for the ITT population. Kaplan-Meier curve for PFS for the ITT population is provided in Figure 2.</p><p>Table 11. Progression Free Survival Time by IRAC Review Based on IMWG Criteria (Stratified Log Rank Test) (ITT Population)</p><table border="0" cellspacing="0" cellpadding="0" style="width:601px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pom+LD</strong>-<strong>Dex</strong></p><p><strong>(N=302)</strong></p></td><td style="vertical-align:top"><p><strong>HD</strong>-<strong>Dex</strong></p><p><strong>(N=153)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Progression free survival (PFS), N</p></td><td style="vertical-align:top"><p>302 (100.0)</p></td><td style="vertical-align:top"><p>153 (100.0)</p></td></tr><tr><td style="vertical-align:top"><p>Censored, n (%)</p></td><td style="vertical-align:top"><p>138 (45.7)</p></td><td style="vertical-align:top"><p>50 (32.7)</p></td></tr><tr><td style="vertical-align:top"><p>Progressed/Died, n (%)</p></td><td style="vertical-align:top"><p>164 (54.3)</p></td><td style="vertical-align:top"><p>103 (67.3)</p></td></tr><tr><td><p>Progression Free Survival Time (weeks)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median <sup>a</sup></p></td><td style="vertical-align:top"><p>15.7</p></td><td style="vertical-align:top"><p>8.0</p></td></tr><tr><td style="vertical-align:top"><p>Two sided 95% CI<sup>b</sup></p></td><td style="vertical-align:top"><p>[13.0, 20.1]</p></td><td style="vertical-align:top"><p>[7.0, 9.0]</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (Pom+LD-Dex:HD-Dex) 2-Sided 95% CI <sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.45 [0.35,0.59]</p></td></tr><tr><td style="vertical-align:top"><p>Log-Rank Test Two sided P-Value <sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr></tbody></table><p>Note: CI=Confidence interval; IRAC=Independent Review AdjudicationCommittee; NE = Not Estimable. a The median is based on Kaplan-Meier estimate.</p><p>b 95% confidence interval about the median progression free survival time.</p><p>c&nbsp; Based on Cox proportional hazards model comparingthe hazard functions associated with treatment groups, stratified by age (&le;75 vs &gt;75),diseases population(refractoryto both Lenalidomide and Bortezomibvs not refractory to both active substances),and prior number of anti myeloma therapy (=2 vs &gt;2).</p><p>d The p-value is based on a stratified log-rank test with the same stratificationfactorsas the above Cox model. Data cutoff: 07 Sep 2012</p><p>Figure 2. Progression Free Survival Based on IRAC Review of Response by IMWG Criteria (Stratified Log Rank Test) (ITT Population)</p><p><!--[if gte vml 1]><v:group id="Group_x0020_70467"
 o:spid="_x0000_s1047" style='position:absolute;left:0;text-align:left;
 margin-left:38.15pt;margin-top:-6.5pt;width:433.2pt;height:261.1pt;z-index:251658240'
 coordsize="55016,33162" o:gfxdata="UEsDBBQABgAIAAAAIQAfiHZoFgEAAFECAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSTW7DIBCF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">
 <v:shape id="Picture_x0020_7710" o:spid="_x0000_s1048" type="#_x0000_t75"
  style='position:absolute;width:55016;height:33162;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBwvGlJwwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9NawIx
EL0L/Q9hCr1p1hZUVqOUslKhWNAWz9Nkulm6maxJ6m7/vTkUPD7e92ozuFZcKMTGs4LppABBrL1p
uFbw+bEdL0DEhGyw9UwK/ijCZn03WmFpfM8HuhxTLXIIxxIV2JS6UsqoLTmME98RZ+7bB4cpw1BL
E7DP4a6Vj0Uxkw4bzg0WO3qxpH+Ov07B6e1V95W2cfbe7s+7ZvH1VFVBqYf74XkJItGQbuJ/984o
mM+neX9+k5+AXF8BAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAcLxpScMAAADdAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
">
  <v:imagedata src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg"
   o:title=""/>
 </v:shape><v:rect id="Rectangle_x0020_7717" o:spid="_x0000_s1049" style='position:absolute;
  left:46390;top:2777;width:1939;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCR5ZNnxgAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pi8Iw
FMTvgt8hPMGbpnqwWo0i/kGPuyqot0fzbIvNS2mi7e6n3yws7HGYmd8wi1VrSvGm2hWWFYyGEQji
1OqCMwWX834wBeE8ssbSMin4IgerZbezwETbhj/pffKZCBB2CSrIva8SKV2ak0E3tBVx8B62NuiD
rDOpa2wC3JRyHEUTabDgsJBjRZuc0ufpZRQcptX6drTfTVbu7ofrx3W2Pc+8Uv1eu56D8NT6//Bf
+6gVxPEoht834QnI5Q8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAkeWTZ8YAAADdAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>HD</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_7718" o:spid="_x0000_s1050" style='position:absolute;
  left:47884;top:2777;width:445;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>-</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_7719" o:spid="_x0000_s1051" style='position:absolute;
  left:48219;top:2777;width:2749;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>DEX</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_7720" o:spid="_x0000_s1052" style='position:absolute;
  left:46390;top:4575;width:5425;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>POM+LD</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_7721" o:spid="_x0000_s1053" style='position:absolute;
  left:50566;top:4575;width:445;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>-</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_7722" o:spid="_x0000_s1054" style='position:absolute;
  left:50901;top:4575;width:2750;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>DEX</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_7730" o:spid="_x0000_s1055" style='position:absolute;
  left:1310;top:26978;width:15762;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>POM+LD-DEX
     vs HD-DEX</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_7731" o:spid="_x0000_s1056" style='position:absolute;
  left:1310;top:28136;width:19702;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>Logrank
     p-value = &lt; 0.001 (2-sided)</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_7732" o:spid="_x0000_s1057" style='position:absolute;
  left:1310;top:29294;width:16616;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>HR (95%
     CI) 0.45 (0.35, 0.59)</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_7733" o:spid="_x0000_s1058" style='position:absolute;
  left:1310;top:30483;width:29004;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>Events:
     POM+LD-DEX=164/302 HD-DEX=103/153</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap type="square"/>
</v:group><![endif]--><img width="578" height="348" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" />1.0</p><p>0.8</p><p>0.6</p><p>0.4</p><p>0.2</p><p>0.0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65</p><p>Progression Free Survival (weeks)</p><p>Data cutoff: 07 Sep 2012</p><p>Overall Survival was the key secondary study endpoint. A total of 226 (74.8%) of the Pom + LD-Dex patients and 95 (62.1%) of the HD-Dex patients were alive as of the cutoff date (07 Sep 2012). Median OS time from Kaplan-Meier estimates has not been reached for the Pom + LD-Dex, but would be expected to be at least 48 weeks, which is the lower boundary of the 95% CI. Median OS time for the HD-Dex arm was 34 weeks (95% CI: 23.4, 39.9). The 1-year event free rate was 52.6% (&plusmn; 5.72%) for the Pom + LD-Dex arm and 28.4% (&plusmn; 7.51%) for the HD-Dex arm. The difference in OS between the two treatment arms was statistically significant (p &lt; 0.001).</p><p>Overall survival is summarised in Table 12 for the ITT population. Kaplan-Meier curve for OS for the ITT population is provided in Figure 3.</p><p>Based on the results of both PFS and OS endpoints, the Data Monitoring Committee established for this study recommended that the study be completed and patients in the HD-Dex arm be crossed over to the</p><p>Pom + LD-Dex arm.</p><p>Table 12. Overall Survival: ITT Population</p><table border="0" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Statistics</strong></p></td><td style="vertical-align:bottom"><p><strong>Pom+LD</strong>-<strong>Dex (N=302)</strong></p></td><td style="vertical-align:top"><p><strong>HD</strong>-<strong>Dex</strong></p><p><strong>(N=153)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>302 (100.0)</p></td><td style="vertical-align:top"><p>153 (100.0)</p></td></tr><tr><td style="vertical-align:top"><p>Censored</p></td><td style="vertical-align:top"><p>n (%)</p></td><td style="vertical-align:top"><p>226 (74.8)</p></td><td style="vertical-align:top"><p>95 (62.1)</p></td></tr><tr><td style="vertical-align:top"><p>Died</p></td><td style="vertical-align:top"><p>n (%)</p></td><td style="vertical-align:top"><p>76 (25.2)</p></td><td style="vertical-align:top"><p>58 (37.9)</p></td></tr><tr><td style="vertical-align:top"><p>Survival Time (weeks)</p></td><td style="vertical-align:top"><p>Mediana</p></td><td style="vertical-align:top"><p>NE</p></td><td style="vertical-align:top"><p>34.0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Two sided 95% CIb</p></td><td style="vertical-align:top"><p>[48.1, NE]</p></td><td style="vertical-align:top"><p>[23.4, 39.9]</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard Ratio (Pom+LD-Dex:HD-Dex) [Two sided 95% CI<sup>c</sup>]</p></td><td colspan="2" style="vertical-align:top"><p>0.53[0.37, 0.74]</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Log-Rank Test Two sided P-Value<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr></tbody></table><p>Note: CI=Confidence interval. NE = Not Estimable. <sup>a </sup>The median is based on Kaplan-Meier estimate. <sup>b </sup>95% confidence interval about the median overall survival time. <sup>c </sup>Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups.</p><p><sup>d </sup>The p-value is based on an unstratified log-rank test. Data cutoff: 07 Sep 2012</p><p>Figure 3. Kaplan-Meier Curve of Overall Survival (ITT Population)</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_71067" o:spid="_x0000_s1026" style='width:467.85pt;height:217.9pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="59416,27675" o:gfxdata="UEsDBBQABgAIAAAAIQAfiHZoFgEAAFECAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSTW7DIBCF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">
 <v:shape id="Picture_x0020_8068" o:spid="_x0000_s1027" type="#_x0000_t75"
  style='position:absolute;left:3851;width:55565;height:27675;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image006.jpg"
   o:title=""/>
 </v:shape><v:rect id="Rectangle_x0020_8069" o:spid="_x0000_s1028" style='position:absolute;
  left:51003;top:2678;width:1660;height:1070;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>HD</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8070" o:spid="_x0000_s1029" style='position:absolute;
  left:52344;top:2678;width:392;height:1070;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCeuquCwwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE89b8Iw
EN0r8R+sq8RWnHYoIWAQoq2SsQUkYDvFRxJhn6PYJYFfXw+VGJ/e92I1WCOu1PnGsYLXSQKCuHS6
4UrBfvf1koLwAVmjcUwKbuRhtRw9LTDTrucfum5DJWII+wwV1CG0mZS+rMmin7iWOHJn11kMEXaV
1B32Mdwa+ZYk79Jiw7GhxpY2NZWX7a9VkKft+li4e1+Zz1N++D7MPnazoNT4eVjPQQQawkP87y60
gjSZxv3xTXwCcvkHAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAnrqrgsMAAADdAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>-</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8071" o:spid="_x0000_s1030" style='position:absolute;
  left:52649;top:2678;width:2430;height:1070;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDx9g4ZxwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvBf/D8gq9NRt7sDFmFbFKPLYq2N4e2WcSmn0bsmuS9td3C4LHYWa+YbLVaBrRU+dqywqmUQyC
uLC65lLB6bh7TkA4j6yxsUwKfsjBajl5yDDVduAP6g++FAHCLkUFlfdtKqUrKjLoItsSB+9iO4M+
yK6UusMhwE0jX+J4Jg3WHBYqbGlTUfF9uBoFedKuP/f2dyib7Vd+fj/P345zr9TT47hegPA0+nv4
1t5rBUn8OoX/N+EJyOUfAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAPH2DhnHAAAA3QAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>DEX</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8072" o:spid="_x0000_s1031" style='position:absolute;
  left:51003;top:3806;width:4780;height:1070;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>POM+LD</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8073" o:spid="_x0000_s1032" style='position:absolute;
  left:54783;top:3806;width:391;height:1070;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>-</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8074" o:spid="_x0000_s1033" style='position:absolute;
  left:55087;top:3806;width:2430;height:1070;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>DEX</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8076" o:spid="_x0000_s1034" style='position:absolute;
  left:5557;top:18047;width:15763;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQB+H5ZtxQAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pi8Iw
FMTvwn6H8Ba8aaoHt1ajyK6iR/8sqLdH82yLzUtpoq376Y0g7HGYmd8w03lrSnGn2hWWFQz6EQji
1OqCMwW/h1UvBuE8ssbSMil4kIP57KMzxUTbhnd03/tMBAi7BBXk3leJlC7NyaDr24o4eBdbG/RB
1pnUNTYBbko5jKKRNFhwWMixou+c0uv+ZhSs42px2ti/JiuX5/Vxexz/HMZeqe5nu5iA8NT6//C7
vdEK4uhrBK834QnI2RMAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQB+H5ZtxQAAAN0AAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>POM+LD-DEX
     vs HD-DEX</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8077" o:spid="_x0000_s1035" style='position:absolute;
  left:5557;top:19388;width:19702;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>Logrank
     p-value = &lt; 0.001 (2-sided)</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8078" o:spid="_x0000_s1036" style='position:absolute;
  left:5557;top:20730;width:16945;height:1216;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>HR (95%
     CI)<span style='mso-spacerun:yes'>  </span>0.53 (0.37, 0.74)</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8079" o:spid="_x0000_s1037" style='position:absolute;
  left:5557;top:22071;width:26551;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>KM
     median: POM+LD-DEX=NE<span style='mso-spacerun:yes'>       </span>[48.1,
     NE]</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8080" o:spid="_x0000_s1038" style='position:absolute;
  left:5557;top:23412;width:23837;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>KM
     median: HD-DEX<span style='mso-spacerun:yes'>   </span>=<span
     style='mso-spacerun:yes'>   </span>34.0[23.4, 39.9]</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8081" o:spid="_x0000_s1039" style='position:absolute;
  left:5557;top:24753;width:27667;height:1217;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>Events:
     POM+LD-DEX=75/284 HD-DEX=56/139</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8082" o:spid="_x0000_s1040" style='position:absolute;
  left:2662;top:789;width:1439;height:1069;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>1.0</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8083" o:spid="_x0000_s1041" style='position:absolute;
  left:2662;top:5940;width:1439;height:1069;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>0.8</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8084" o:spid="_x0000_s1042" style='position:absolute;
  left:2662;top:10969;width:1439;height:1069;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>0.6</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8085" o:spid="_x0000_s1043" style='position:absolute;
  left:2662;top:16120;width:1439;height:1070;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>0.4</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8086" o:spid="_x0000_s1044" style='position:absolute;
  left:2662;top:21149;width:1439;height:1070;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>0.2</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8087" o:spid="_x0000_s1045" style='position:absolute;
  left:2662;top:26300;width:1439;height:1070;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:7.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>0.0</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_8096" o:spid="_x0000_s1046" style='position:absolute;
  left:-5804;top:13490;width:13009;height:1401;rotation:-5898239fd;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0cm;margin-right:0cm;margin-bottom:
     8.0pt;margin-left:0cm;text-indent:0cm;line-height:107%'><span
     style='font-size:9.0pt;mso-bidi-font-size:11.0pt;line-height:107%'>Propotion
     of Patients</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="625" height="290" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:467.85pt;height:217.9pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65</p><p>Overall Survival (week)</p><p>cutoff: 07 Sep 2012</p><p>&nbsp;</p><p>Paediatric population<br />In a Phase 1 single-arm, open-label, dose<br />escalation study, the maximum tolerated dose<br />(MTD) and/or recommended Phase2 dose<br />(RP2D) of pomalidomide in paediatric patients<br />was determined to be 2.6 mg/m2/day<br />administered orally on Day 1 to Day 21 of a<br />repeated 28-day cycle.<br />Efficacy was not demonstrated in a Phase 2<br />multi-centre, open-label, parallel-group study<br />conducted in 52 pomalidomide-treated paediatric<br />patients, aged 4 to 18 years with recurrent or<br />progressive highgrade<br />glioma, medulloblastoma, ependymoma or<br />diffuse intrinsic pontine glioma (DIPG) with<br />primary location in the central nervous system<br />(CNS).<br />In the Phase 2 study, two patients in the highgrade<br />glioma group (N=19) achieved a response<br />as defined by protocol; one of these patients<br />achieved a partial response (PR) and the other<br />patient achieved a long term stable disease (SD),<br />which resulted in an objective response (OR) and<br />long-term SD rate of 10.5% (95% CI: 1.3, 33.1).<br />One patient in the ependymoma group (N=9)<br />achieved a long- term SD which resulted in an<br />OR and long-term SD rate of 11.1% (95% CI:<br />0.3, 48.2). No confirmed OR or long-term SD<br />was observed in any of the evaluable patients in<br />either the diffuse intrinsic pontine glioma<br />(DIPG) group (N=9) or medulloblastoma group<br />(N=9). None of the 4 parallel groups assessed in<br />this Phase 2 study met the primary endpoint of<br />objective response or long-term stable disease<br />rate.<br />The overall safety profile of pomalidomide in<br />paediatric patients was consistent with the known</p><p>safety profile in adults. Pharmacokinetic (PK)<br />parameters were evaluated in an Integrated PK<br />Analysis of the Phase 1 and Phase 2 studies and<br />were found to have no significant difference to<br />those observed in adult patients (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Pomalidomide is absorbed with a maximum plasma concentration (C<sub>max</sub>) occurring between 2 and 3 hours and is at least 73% absorbed following administration of single oral dose. The systemic exposure (AUC) of pomalidomide increases in an approximately linear and dose proportional manner. Following multiple doses, pomalidomide has an accumulation ratio of 27 to 31% on AUC.</p><p>Coadministration with a high-fat and high-calorie meal slows the rate of absorption, decreasing mean plasma C<sub>max </sub>by approximately 27%, but has minimal effect on the overall extent of absorption with an 8% decrease in mean AUC. Therefore, pomalidomide can be administered without regard to food intake.</p><p>Distribution</p><p>Pomalidomide has a mean apparent volume of distribution (Vd/F) between 62 and 138 L at steady state. Pomalidomide is distributed in semen of healthy subjects at a concentration of approximately 67% of plasma level at 4 hours post-dose (approximately T<sub>max</sub>) after 4 days of once daily dosing at 2 mg. <em>In vitro </em>binding of pomalidomide enantiomers to proteins in human plasma ranges from 12% to 44% and is not concentration dependent.</p><p>Biotransformation</p><p>Pomalidomide is the major circulating component (approximately 70% of plasma radioactivity) <em>in vivo </em>in healthy subjects who received a single oral dose of [<sup>14</sup>C]-pomalidomide (2 mg). No metabolites were present at &gt;10% relative to parent or total radioactivity in plasma.</p><p>The predominant metabolic pathways of excreted radioactivity are hydroxylation with subsequent glucuronidation, or hydrolysis. <em>In vitro</em>, CYP1A2 and CYP3A4 were identified as the primary enzymes involved in the CYP-mediated hydroxylation of pomalidomide, with additional minor contributions from CYP2C19 and CYP2D6. Pomalidomide is also a substrate of P-glycoprotein <em>in vitro</em>. Co-administration of pomalidomide with the strong CYP3A4/5 and P-gp inhibitor ketoconazole, or the strong CYP3A4/5 inducer carbamazepine, had no clinically relevant effect on exposure to pomalidomide. Co-administration of the strong CYP1A2 inhibitor fluvoxamine with pomalidomide in the presence of ketoconazole, increased mean exposure to pomalidomide by 107% with a 90% confidence interval [91% to 124%] compared to pomalidomide plus ketoconazole. In a second study to evaluate the contribution of a CYP1A2 inhibitor alone to metabolism changes, co-administration of fluvoxamine alone with pomalidomide increased mean exposure to pomalidomide by 125% with a 90% confidence interval [98% to 157%] compared to pomalidomide alone. If strong inhibitors of CYP1A2 (e.g. ciprofloxacin, enoxacin and fluvoxamine) are co-administered with pomalidomide, reduce the dose of pomalidomide to 50%. Administration of pomalidomide in smokers, with smoking tobacco known to induce the CYP1A2 isoform, had no clinically relevant effect on exposure to pomalidomide compared to that exposure to pomalidomide observed in non-smokers.</p><p>Based on <em>in vitro </em>data, pomalidomide is not an inhibitor or inducer of cytochrome P-450 isoenzymes, and does not inhibit any drug transporters that were studied. Clinically relevant drug-drug interactions are not anticipated when pomalidomide is coadministered with substrates of these pathways.</p><p>Elimination</p><p>Pomalidomide is eliminated with a median plasma half-life of approximately 9.5 hours in healthy subjects and approximately 7.5 hours in patients with multiple myeloma. Pomalidomide has a mean total body clearance (CL/F) of approximately 7-10 L/hr.</p><p>Following a single oral administration of [<sup>14</sup>C] -pomalidomide (2 mg) to healthy subjects, approximately</p><p>73% and 15% of the radioactive dose was eliminated in urine and faeces, respectively, with approximately 2% and 8% of the dosed radiocarbon eliminated as pomalidomide in urine and faeces.</p><p>Pomalidomide is extensively metabolised prior to excretion, with the resulting metabolites eliminated primarily in the urine. The 3 predominant metabolites in urine (formed via hydrolysis or hydroxylation with subsequent glucuronidation) account for approximately 23%, 17%, and 12%, respectively, of the dose in the urine.</p><p>CYP dependent metabolites account for approximately 43% of the total excreted radioactivity, while nonCYP dependent hydrolytic metabolites account for 25%, and excretion of unchanged pomalidomide accounted for 10% (2% in urine and 8% in faeces).</p><p>Population Pharmacokinetics (PK)</p><p>Based on population PK analysis using a two-compartment model, healthy subjects and MM patients had comparable apparent clearance (CL/F) and apparent central volume of distribution (V<sub>2</sub>/F). In peripheral tissues, pomalidomide was preferentially taken up by tumors with apparent peripheral distribution clearance (Q/F) and apparent peripheral volume of distribution (V<sub>3</sub>/F) 3.7-fold and 8-fold higher, respectively, than that of healthy subjects.</p><p><u>Paediatric population</u></p><p>Following a single oral dose of pomalidomide in<br />children and young adults with recurrent or<br />progressive primary brain tumour, the median<br />Tmax was 2 to 4 hours post-dose and<br />corresponded to geometric mean Cmax (CV%)<br />values of 74.8 (59.4%), 79.2 (51.7%), and 104<br />(18.3%) ng/mL at the 1.9, 2.6, and 3.4 mg/m2<br />dose levels, respectively. AUC0-24 and AUC0-inf<br />followed similar trends, with total exposure in<br />the range of approximately 700 to 800 h&middot;ng/mL<br />at the lower 2 doses, and approximately 1200<br />h&middot;ng/mL at the high dose. Estimates of half-life<br />were in the range of approximately 5 to 7<br />hours. There were no clear trends attributable<br />to stratification by age and steroid use at the<br />MTD.<br />Overall, data suggest that AUC increased nearly<br />proportional to the increase in pomalidomide<br />dose, while the increase in Cmax was generally<br />less than proportional.<br />The pharmacokinetics of pomalidomide following<br />oral administration dose levels of 1.9 mg/m2/day<br />to<br />3.4 mg/m2/day were determined in 70 patients<br />with ages from 4 to 20 years in an integrated<br />analysis of a Phase 1 and Phase 2 study in<br />recurrent or progressive paediatric brain<br />tumours. Pomalidomide concentration-time<br />profiles were adequately described with a one<br />compartment PK model with first- order<br />absorption and elimination. Pomalidomide<br />exhibited linear and time-invariant PK with<br />moderate variability. The typical values of CL/F,</p><p>Vc/F, Ka, lag time of pomalidomide were 3.94<br />L/h, 43.0 L,<br />1.45 h-1 and 0.454 h respectively. The terminal<br />elimination half-life of pomalidomide was 7.33<br />hours. Except for body surface area (BSA),<br />none of the tested covariates including age and<br />sex had effect on pomalidomide PK. Although<br />BSA was identified as a statistically significant<br />covariate of pomalidomide CL/F and Vc/F, the<br />impact of BSA on exposure parameters was not<br />deemed clinically relevant.<br />In general, there is no significant difference of<br />pomalidomide PK between children and adult<br />patients.</p><p>Elderly</p><p>Based on population pharmacokinetic analyses in healthy subjects and multiple myeloma patients, no significant influence of age (19-83 years) on oral clearance of pomalidomide was observed. In clinical studies, no dose adjustment was required in elderly (&gt; 65 years) patients exposed to pomalidomide (see section 4.2).</p><p>Renal impairment</p><p>Population pharmacokinetic analyses showed that the pomalidomide pharmacokinetic parameters were not remarkably affected in renally impaired patients (defined by creatinine clearance or estimated glomerular filtration rate [eGFR]) compared to patients with normal renal function</p><p>(CrCl &ge;60 mL/minute). Mean normalised AUC exposure to pomalidomide was 98.2% with a</p><p>90% confidence interval [77.4% to 120.6%] in moderate renal impairment patients (eGFR &ge;30 to &le;45 mL/minute/1.73 m2) compared to patients with normal renal function. Mean normalised AUC exposure to pomalidomide was 100.2% with a 90% confidence interval [79.7% to 127.0%] in severe renal impairment patients not requiring dialysis (CrCl &lt;30 or eGFR &lt;30 mL/minute/1.73 m2) compared to patients with normal renal function. Mean normalised AUC exposure to pomalidomide increased by 35.8% with a 90% CI [7.5% to 70.0%] in severe renal impairment patients requiring dialysis (CrCl &lt;30mL/minute requiring dialysis) compared to patients with normal renal function. The mean changes in exposure to pomalidomide in each of these renal impairment groups are not of a magnitude that requires dosage adjustments.</p><p>Hepatic impairment</p><p>The pharmacokinetic parameters were modestly changed in hepatically impaired patients (defined by Child-Pugh criteria) compared to healthy subjects. Mean exposure to pomalidomide increased by 51% with a 90% confidence interval [9% to 110%] in mildly hepatically impaired patients compared to healthy subjects. Mean exposure to pomalidomide increased by 58% with a 90% confidence interval [13% to 119%] in moderately hepatically impaired patients compared to healthy subjects. Mean exposure to pomalidomide increased by 72% with a 90% confidence interval [24% to 138%] in severely hepatically impaired patients compared to healthy subjects. The mean increases in exposure to pomalidomide in each of these impairment groups are not of a magnitude for which adjustments in schedule or dose are required (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeat-dose toxicology studies</p><p>In rats, chronic administration of pomalidomide at doses of 50, 250, and 1000 mg/kg/day for 6 months was well tolerated. No adverse findings were noted up to 1000 mg/kg/day (175-fold exposure ratio relative to a 4 mg clinical dose).</p><p>In monkeys, pomalidomide was evaluated in repeat-dose studies of up to 9 months in duration. In these studies, monkeys exhibited greater sensitivity to pomalidomide effects than rats. The primary toxicities observed in monkeys were associated with the haematopoietic/lymphoreticular systems. In the 9-month study in monkeys with doses of 0.05, 0.1, and 1 mg/kg/day, morbidity and early euthanasia of 6 animals were observed at the dose of 1 mg/kg/day and were attributed to immunosuppressive effects (staphylococcal infection, decreased peripheral blood lymphocytes, chronic inflammation of the large intestine, histologic lymphoid depletion, and hypocellularity of bone marrow) at high exposures of pomalidomide (15-fold exposure ratio relative to a 4 mg clinical dose). These immunosuppressive effects resulted in early euthanasia of 4 monkeys due to poor health condition (watery stool, inappetence, reduced food intake, and weight loss); histopathologic evaluation of these animals showed chronic inflammation of the large intestine and villous atrophy of the small intestine. Staphylococcal infection was observed in 4 monkeys; 3 of these animals responded to antibiotic treatment and 1 died without treatment. In addition, findings consistent with acute myelogenous leukemia led to euthanasia of 1 monkey; clinical observations and clinical pathology and/or bone marrow alterations observed in this animal were consistent with immunosuppression. Minimal or mild bile duct proliferation with associated increases in ALP and GGT were also observed at 1 mg/kg/day. Evaluation of recovery animals indicated that all treatment-related findings were reversible after 8 weeks of dosing cessation, except for proliferation of intrahepatic bile ducts observed in 1 animal in the 1 mg/kg/day group. The No Observed Adverse Effect Level (NOAEL) was 0.1 mg/kg/day (0.5-fold exposure ratio relative to a 4 mg clinical dose).</p><p>Genotoxicity/carcinogenicity</p><p>Pomalidomide was not mutagenic in bacterial and mammalian mutation assays, and did not induce chromosomal aberrations in human peripheral blood lymphocytes or micronuclei formation in polychromatic erythrocytes in bone marrow of rats administered doses up to 2000 mg/kg/day. Carcinogenicity studies have not been conducted.</p><p>Fertility and early embryonic development</p><p>In a fertility and early embryonic development study in rats, pomalidomide was administered to males and females at dosages of 25, 250, and 1000 mg/kg/day. Uterine examination on Gestation Day 13 showed a decrease in mean number of viable embryos and an increase in postimplantation loss at all dosage levels. Therefore, the NOAEL for these observed effects was &lt; 25 mg/kg/day (AUC <sub>24h </sub>was 39960 ng&bull;h/mL (nanogram&bull;hour/millilitres) at this lowest dose tested, and the exposure ratio was 99-fold relative to a 4 mg clinical dose). When treated males on this study were mated with untreated females, all uterine parameters were comparable to the controls. Based on these results, the observed effects were attributed to the treatment of females.</p><p>Embryo-foetal development</p><p>Pomalidomide was found to be teratogenic in both rats and rabbits when administered during the period of major organogenesis. In the rat embryofoetal developmental toxicity study, malformations of absence of urinary bladder, absence of thyroid gland, and fusion and misalignment of lumbar and thoracic vertebral elements (central and/or neural arches) were observed at all dosage levels (25, 250, and 1000 mg/kg/day).</p><p>There was no maternal toxicity observed in this study. Therefore, the maternal NOAEL was</p><p>1000 mg/kg/day, and the NOAEL for developmental toxicity was &lt; 25 mg/kg/day (AUC<sub>24h </sub>was 34340 ng&bull;h/mL on Gestation Day 17 at this lowest dose tested, and the exposure ratio was 85-fold relative to a 4 mg clinical dose). In rabbits, pomalidomide at dosages ranging from 10 to 250 mg/kg produced embryo-foetal developmental malforma tions. Increased cardiac anomalies were seen at all doses with significant increases at 250 mg/kg/day. At 100 and 250 mg/kg/day, there were slight increases in post-implantation loss and slight decreases in fetal body weights. At 250 mg/kg/day, fetal malformations included limb anomalies (flexed and/or rotated fore- and/or hindlimbs, unattached or absent digit) and associated skeletal malformations (not ossified metacarpal, misaligned phalanx and metacarpal, absent digit, not ossified phalanx, and short not ossified or bent tibia); moderate dilation of the lateral ventricle in the brain; abnormal placement of the right subclavian artery; absent intermediate lobe in the lungs; low-set kidney; altered liver morphology; incompletely or not ossified pelvis; an increased average for supernumerary thoracic ribs and a reduced average for ossified tarsals. Slight reduction in maternal body weight gain, significant reduction in triglycerides, and significant decrease in absolute and relative spleen weights were observed at 100 and 250 mg/kg/day. The maternal NOAEL was 10 mg/kg/day, and the developmental NOAEL was &lt;10 mg/kg/day (AUC<sub>24h </sub>was 418 ng&bull;h/mL on</p><p>Gestation Day 19 at this lowest dose tested, which was similar to that obtained from a 4 mg clinical dose).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsule contents</p><p>Mannitol (E421)</p><p>Starch, pregelatinised</p><p>Sodium stearyl fumarate</p><p>Capsule shell</p><p>Imnovid 1 mg hard capsules Gelatin</p><p>Titanium dioxide (E171)</p><p>Indigotine (E132)</p><p>Yellow iron oxide (E172) White and black ink</p><p>Imnovid 2 mg hard capsules Gelatin</p><p>Titanium dioxide (E171)</p><p>Indigotine (E132)</p><p>Yellow iron oxide (E172)</p><p>Erythrosin (E127)</p><p>White ink</p><p>Imnovid 3 mg hard capsules Gelatin</p><p>Titanium dioxide (E171)</p><p>Indigotine (E132)</p><p>Yellow iron oxide (E172) White ink</p><p>Imnovid 4 mg hard capsules Gelatin</p><p>Titanium dioxide (E171)</p><p>Indigotine (E132)</p><p>Brilliant blue FCF (E133)</p><p>White ink</p><p>Printing ink</p><p><em><u>Imnovid 1 mg hard capsules</u></em></p><p>White ink</p><p>Shellac</p><p>Titanium dioxide (E171)</p><p>Simeticone</p><p>Propylene glycol (E1520)</p><p>Ammonium hydroxide (E527)</p><p>Black ink</p><p>Shellac</p><p>Iron oxide black (E172)</p><p>Propylene glycol (E1520)</p><p>Ammonium hydroxide (E527)</p><p><em><u>Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules</u></em></p><p>White ink</p><p>Shellac</p><p>Titanium dioxide (E171)</p><p>Simeticone</p><p>Propylene glycol (E1520)</p><p>Ammonium hydroxide (E527)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30<sup>o</sup>C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The capsules are packaged in Polyvinyl chloride (PVC)/ polychlorotrifluoroethylene (PCTFE) blisters with push through aluminium foil.</p><p>Pack size of 21 capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsules should not be opened or crushed. If powder from pomalidomide makes contact with the skin, the skin should be washed immediately and thoroughly with soap and water. If pomalidomide makes contact with the mucous membranes, they should be thoroughly flushed with water.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Unused medicinal product should be returned to the pharmacist at the end of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bristol-Myers Squibb Pharma EEIG
Plaza 254
Blanchardstown Corporate Park 2
Dublin 15, D15 T867
Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>